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CHAPTER I 
INTRODUCTION 
Although contemporary medicine has celebrated 
remarkable success in the treatment of symptoms and 
etiology of microbial infections, the incidence of 
progressively debilitating diseases such as 
cardiovascular, neoplastic and neurological diseases has 
increased unabated. Second only to heart disease in 
incidence, cancer is a disease characterized by germ line 
mutations and progressive accumulation of somatic 
mutations in genes regulating cellular growth and 
differentiation. Of over forty chemotherapeutic agents 
approved for clinical use, no single, polypharmaceutical, 
or multi-modality therapies have served as the 
"mithridieum", or the magic bullet, for the eradication 
of neoplastic disease in humans. 
The oncologist has used chemotherapy as a front line 
therapy, or in an adjuvant setting with radiation 
therapy, hypothermia, and surgery in combating neoplastic 
disease. Curative regimens for the relatively rare adult 
neoplastic transformations of testicular and 
hematopoietic cells have been developed. However, more 
common forms of neoplasms such as colon, lung, and breast 
cancer have been refractory to chemotherapeutics which 
target neoplastic DNA and intermediary metabolism. 
Drug resistance can be defined as the ability of the 
tumor cell to survive exposure to cytostatic and 
cytocidal agents when administered at the maximum dose 
tolerated by normal cells. This phenomenon is an 
interactive consequence of a number of host and tumor 
cell factors. Host factors include drug absorption, 
distribution, metabolism, and excretion which can 
decrease the bioavailability of agents to the tumor site. 
Tumor cells possess a number of biochemical mechanisms of 
drug resistance that decrease the intracellular 
bioavailability of chemotherapeutic agents and facilitate 
the repair of macromolecular damage inflicted by these 
drugs. The ultimate obstacle to therapeutic success is 
the ability of the tumor cell to survive relatively 
lethal concentrations of chemotherapeutic agents (O'Brien 
and Cordon-Cardo, 1991). Therefore, the identification 
and selective inactivation of drug resistance mechanisms 
could increase the therapeutic index of an anti-
neoplastic agent. 
A class of anti-neoplastic agents, the 
chloroethylnitrosoureas (CENUs), has been employed in the 
treatment of primary brain tumors, malignant melanoma, 
Hodgkin's and non-Hodgkin's lymphomas, and multiple 
myeloma, with encouraging results (Young, et al., 1971; 
2 
Walker, 1973; Wilson, et al., 1976, Mortel, 1978). 
However, the CENUs produce anti-tumor responses in fewer 
than 20% of patients with non-hematological malignancies, 
suggesting that the majority of human malignancies are 
inherently resistant to the cytotoxic effects of these 
agents (Carter, et al., 1976). Evidence suggests this 
limited effectiveness of CENUs is due to the presence of 
the DNA repair protein, 0 6 -methylguanine DNA 
methyltransferase (MGMT) in tumor cells (Myrnes et al., 
1984,; Chen, et al., 1992; Citron, et al.1991). This 
protein prevents the formation of the cytotoxic lesion 
induced by CENU, the DNA interstrand cross-link 
(Erickson, et al., 1980a; Yarosh, et al., 1983). 
This dissertation describes pre-clinical studies 
aimed at developing a novel chemotherapeutic regimen that 
targets the extended depletion of MGMT in order to 
increase the therapeutic effectiveness of one of the 
CENUs, 1,3 bis(2-chloroethyl)-1-nitrosourea (BCNU). This 
regimen consists of the sequential administration of two 
MGMT depleting agents, 0 6 -benzylguanine (BG) and 
streptozotocin (STZ), prior to BCNU treatment. 
Considerable evidence suggests that pretreatment of 
resistant cells with MGMT depleting agents prior to CENU 
exposure increases DNA cross-link formation and 
cytotoxicity in resistant cells (Zlotogorski and 
Erickson, 1983, 1984; Dolan et al., 1988; Dolan et al., 
3 
1990a,b). The observation that the DNA interstrand 
cross-link precursor 0 6 , N1 ethanoguanine is stable in 
CENU treated DNA for greater than 8 hr following drug 
removal suggests that the potential for cross-link 
formation exists for extended periods (Brent, 1985b). 
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DNA interstrand cross-links produced by CENUs continue to 
form 6-12 hr after drug removal in MGMT deficient cells 
(Erickson et al., 1980a). These data suggest that 
extended depletion of MGMT throughout the time-course of 
cross-link formation could maximize CENU cross-linking 
and cytotoxicity. If functional MGMT recovers during the 
time-frame of cross-link formation in resistant cells, 
then the enhancement of CENU cytotoxicity by MGMT 
depleting agents would be sub-maximal. The importance of 
recovery of MGMT activity following MGMT depleting agents 
in determining the potentiation of CENU cytotoxicity has 
largely been neglected. Therefore, experiments described 
within this dissertation test the following hypothesis; 
depletion of MGMT prior to, and for an extended period 
following BCNU administration maximizes BCNU anti-tumor 
activity in resistant cells. In testing this hypothesis, 
the combination of 0 6 -benzylguanine (BG) and 
streptozotocin (STZ) was used in an effort to produce a 
more extended depletion of MGMT, and a greater 
enhancement of BCNU cytotoxicity than either STZ or BG 
alone. The enhancement of BCNU cytotoxicity was measured 
5 
under conditions of extended depletion of MGMT for 24 hr 
with the combination of BG+STZ, partial or complete 
recovery of MGMT by 24 hr with BG or STZ as single 
agents. The combination of BG+STZ produced a more 
prolonged depletion of MGMT and potentiated BCNU 
cytotoxicity to a greater extent than either BG or STZ 
alone. However, the combination of BG+STZ+BCNU provided 
no greater anti-tumor activity than BG+BCNU in vivo. The 
combination of BG+BCNU produced greater anti-tumor 
activity than STZ+BCNU, and equivalent anti-tumor 
activity to that of the three-drug combination. These 
data demonstrate that extended depletion of MGMT 
following BCNU treatment is required to maximize BCNU 
cytotoxicity. Additionally, the sequential use of BG, 
STZ and BCNU probably results in a greater number of STZ 
lesions which are responsible for the continued depletion 
of MGMT and the greater enhancement of BCNU cytotoxicity 
in vitro. 
Collectively, these data suggest that clinical 
regimens targeting the inactivation of MGMT and the 
reversal of CENU resistance should be optimized such that 
MGMT is depleted for extended periods following BCNU 
administration. Although BG can efficiently deplete MGMT 
for prolonged periods in vitro and in vivo, it may not be 
possible to achieve ample concentrations of BG to 
inactivate MGMT in tumors with high levels of the protein 
for a prolonged period. A possible means of reaching 
this objective is by the combined use of the two MGMT 
depleting agents, BG and STZ. 
6 
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CHAPTER II 
REVIEW OF RELATED LITERATURE 
Upon organization of the National Cancer Institute's 
Chemotherapy Program in 1955, several transplantable 
mouse tumors were selected for the evaluation of 
potential anti-neoplastics because clinically useful 
chemotherapeutic agents were effective against one or 
more of these tumors (Gellhorn and Hirschberg, 1955). 
Among these, systemic leukemia L1210 cells responds to 
the greatest number of novel compounds of potential 
clinical interest. 
The 2-chloroethyl derivatives of the DNA methylating 
agents 1-methyl-3-nitro-nitrosoguanidine (MNNG) and 1-
methyl-1-nitrosourea (MNU) showed greater anti-tumor 
activity than the parent compounds in the L1210 leukemia 
model (Skinner et al., 1960, Johnston et al., 1963). 
Shortly thereafter, Skipper et al. (1964) at the Southern 
Research Institute demonstrated the curative ability of 
BCNU against L1210 cells. 1-(2-chloroethyl)-3-
cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-
(4-methylcyclohexyl)-l-nitrosourea (meCCNU) were 
subsequently synthesized and showed similar anti-tumor 
activity against Ll210 leukemia and Lewis lung carcinoma 
implants (Schabel, 1967, Mayo et al., 1972). The anti-
tumor activities of the 1,3 di-substituted nitrosoureas 
against a wide variety of rodent neoplasms has been 
compiled by Schabel (1976). This remarkable anti-tumor 
activity produced by CENUs in mice led to the clinical 
use of BCNU (Carmustine), CCNU (Lomustine), meCCNU 
(Semustine), chlorozotocin, clomesone, and 1-(4-amino-2-
methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-
nitrosourea (ACNU) . 
Mechanism of Action of Chloroethylnitrosoureas 
The macromolecular damage caused by the CENUs 
includes alkylation of nucleic acids and carbamoylation 
of lipids and proteins. However, their antitumor 
activity appears to be the consequence of DNA alkylation. 
Among the plethora of base modifications, the di-adduct 
DNA interstrand cross-link has been demonstrated as the 
prominent cytotoxic lesion (Ewig and Kohn, 1977; Erickson 
et al, 1980 a,b; Kohn et al, 1981). 
At physiologic pH, CENU decompose into an alkylating 
moiety (a chloroethyl diazo hydroxide which further 
decomposed to yield a chloroethyl carbonium ion) and a 
carbamoylating moiety (chloroethyl isocyanate) 
(Montgomery, et al., 1967). The formation of the DNA 
interstrand cross-link occurs in a two-step reaction. 
Cross-linking is thought to involve primary 
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chloroethylation of a nucleophilic site on one strand of 
DNA, with nucleophilic displacement of c1-, and subsequent 
reaction with the opposite strand of DNA, resulting in a 
covalent alkyl bridge between the two strands of DNA 
(Kohn, 1977). Initially, the chloroethyl carbonium ion 
reacts with the 0 6 position of guanine within DNA and 
produces 0 6 -chloroethylguanine (Tong et al., 1981). This 
monoadduct undergoes a slow intramolecular rearrangement 
to form an 0 6 , N1 -ethanoguanine. This cyclized 
intermediate reacts with its complementary base cytosine 
to form N1 -guanine, N3 -cytosine DNA interstrand cross-link 
(Tong et al., 1982) The initial alkylation and 
cyclization requires a low activation energy and is 
complete within minutes, whereas the later reaction 
necessitates a higher activation energy and can take up 
to 6-10 hr at 37°C for completion (Lown et al., 1978) 
This time-course of cross-link formation appears to be 
similar in isolated DNA (Kohn, 1977; Lown et al., 1978) 
and DNA repair deficient cells (Erickson et al., 1980a) 
The formation of DNA interstrand cross-links correlates 
with inhibition of DNA replication and RNA transcription, 
induction of G2 arrest and cytotoxicity (Gralla et al., 
1987; Pieper et al., 1989; Jiang et al., 1989). The 
importance of DNA cross-linking is further evidenced by 
the sensitization of CENU resistant cells with drug 
resistance modulators. Depletion of the DNA repair 
10 
protein MGMT by STZ or BG results in an increased number 
of cross-links and an enhancement of CENU cytotoxicity 
(Futscher et al, 1989; Mitchell et al, 1992) These 
studies will be described further below. 
Alkylation of DNA is currently thought to be of 
greater importance in mediating the anti-tumor activity 
of CENUs than carbamoylation damage. Although the rank 
order of carbamoylating activity of a number of 
nitrosoureas does not correlate with anti-tumor activity 
(Heal et al, 1979; Wheeler et al, 1974), this activity 
may have clinical importance. The effects of 
carbamoylation on cellular metabolism have been 
extensively reviewed by Lea (1987) . 
The primary clinical implications of macromolecular 
carbamoylation damage resides in the CENU-mediated 
inhibition of DNA repair and in the delayed 
myelosuppression caused by CENU (Sarabin et al., 1984; 
Ali-Osman, 1985). The chloroethyl isocyanate 
carbamoylates the epsilon amino groups of lysine or 
arginine residues in various cellular proteins (Holtham 
and Schutz, 1949). Carbamoylation alters protein 
solubility and thereby limits protein function (Holtham 
and Schutz, 1949). 
11 
Carbamoylation and the Inhibition of DNA Repair 
Using organic isocyanate derivatives of CENU, Kann et 
al. (1974) demonstrated a marked inhibition in the repair 
of X-irradiation-induced DNA single strand breaks. A 
subsequent study by Fornace et al. (1978) identified the 
step most sensitive to carbamoylation damage as the re-
ligation of ultraviolet radiation-induced single strand 
breaks. The 2-chloroethyl isocyanate did not impair the 
production of strand breaks and repair polymerase 
activity, but inhibited DNA ligase activity. These 
observations suggest that the impairment of DNA ligase 
activity is indicative of the inhibition of an excision 
repair type mechanism which may contribute to the 
cytotoxicity arising from CENU alkylation damage. 
However, numerous studies suggest that carbamoylation 
damage can inhibit DNA repair but can not substantially 
contribute to the therapeutic effectiveness of CENU. 
Clinically relevant doses of 2-chloroethyl isocyanate 
(i.e. those approximated to be produced by lOOµM BCNU and 
CCNU) do not inhibit repair of gamma-irradiation-induced 
strand breaks and are non-toxic to L1210 or HeLa cells 
(Hilton et al., 1978). This contention is further 
supported by the comparative effects on DNA repair and 
cytotoxicity of two D-glucopyranosyl derivatives of MNU 
with similar alkylating properties and divergent 
carbamoylating activity. The inhibition of DNA repair by 
12 
the carbamoylating agent 3-beta-D-glucopyranosyl-1-
methyl-1-nitrosourea (GMNU) does not produce any greater 
cytotoxicity than its non-carbamoylating congener STZ 
(Heal, et al, 1979). This inhibition of DNA repair could 
have clinical relevance in radioresistance and may 
explain the observed therapeutic synergism by the 
combined administration of two CENUs (Kann et al, 1980; 
Skipper, 1965). The induction of DNA strand breaks 
appears to be a primary mechanism of cell killing by X-
irradiation. Therefore, potent carbamoylating agents 
like 1,3-bis (trans-4-hydorxycyclohexyl)-1-nitrosourea 
(BCyNU) could be used to enhance the anti-tumor activity 
of ionizing radiation (Kann et al., 1980). Similarly, 
the synergism between combined administration of two 
CENUs could also be attributed to the inhibition of DNA 
repair. The direct interaction of CENUs and partially 
purified MGMT results in the inactivation of the protein 
(Brent, 1985a), presumably via carbamoylation. 
Furthermore, excision repair has been implicated in BCNU 
resistance (Swinnen, et al., 1991). Therefore, 
inactivation of one or both of these repair systems could 
be the basis of the synergistic interaction of CENUs 
observed when they were co-administered against rodent 
tumors. 
13 
Carbamoylation and CENU Induced Myelosuppression 
Delayed myelosuppression is the dose limiting 
toxicity of CENUs (Carter et al., 1972; Schein et al., 
1975; Montgomery, 1976; Johnston, et al., 1986). The 
involvement of carbamoylation damage in the etiology of 
myelosuppression is ambiguous. The relative lack of bone 
marrow toxicity of chlorozotocin (a CENU devoid of in 
vitro carbamoylating activity and potent DNA cross-
linking ability) suggests carbamoylation positively 
relates to myelosuppression (Anderson et al., 1975; 
Panasci et al., 1979). However, other evidence suggest 
that carbamoylation may not be responsible for 
myelosuppression. The relative in vitro carbamoylating 
activity of several CENUs and methylnitrosoureas does not 
correlate with bone marrow toxicity in mice (Panasci et 
al., 1977; Brubaker et al., 1987). Only a modest 
relationship exists between the in vitro carbamoylation 
activity and myelosuppression (Heal et al., 1979). ACNU 
and 1-(2-chloroethyl)-3-(1-deoxycyclo-inositol)-1-
nitrosourea, which has little in vitro carbamoylating 
activity, produces comparable bone marrow toxicity to the 
potent carbamoylating agent CCNU. Additionally, another 
potent carbamoylating agent 1-(2-chloroethyl)-3-(beta-D-
glucopyranosyl)-l-nitrosourea (GANU) is not 
myelosuppressive. The significance of these data is 
difficult to evaluate in light of the observations made 
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by Gibson and Hickman (1982) that the in vitro 
carbamoylating activity may not be predictive of in vivo 
carbamoylation. Experiments comparing BCNU, 
chlorozotocin, GANU, and BCyNU-induced myelosuppression 
suggest that myelosuppression may be associated more with 
the qualitative types of carbamoylation damage than the 
amount of damage (Ali-Osman et al., 1985). 
The Relative Importance of Alkylation and Carbamoylation 
Damage in CENU Cytotoxicity 
A reductionist consideration of nitrosourea mechanism 
of action in terms of alkylation versus carbamoylation 
damage is "obviously simplistic" (Lea, 1987). The type 
of carbamoylating moiety within a CENU determines its 
lipid solubility and influences a number of 
pharmacokinetic parameters (Hansch et al., 1972; Levin 
and Kabra, 1974). Once the drug localizes to the tumor, 
alkylation damage could be of primary importance in 
cytotoxicity (Lea, 1987) . As previously stated, the rank 
order of carbamoylating activity of a number nitrosoureas 
does not correlate with the anti-tumor activity (Heal, et 
al., 1979; Wheeler, et al., 1974). Chlorozotocin, a CENU 
with high cross-linking ability and minimal 
carbamoylating activity, produces marginal anti-tumor 
activity compared to congeners with both carbamoylating 
and chloroethylating activity (Gibson and Hickman, 1982) 
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Another potent carbamoylating agent, BCyNU devoid of 
alkylating activity does not produce anti-tumor activity 
(Kann et al., 1980). The compound cis-2-0H-CCNU which 
has lower carbamoylating activity than its parent 
compound CCNU retains full anti-tumor activity (Wheeler, 
1977). Furthermore, a convincing body of data correlating 
CENU anti-tumor activity and DNA cross-linking in tumor 
cell lines and xenografts suggests that the primary mode 
of cell killing is due to alkylation of DNA (Kohn et al., 
1981; Thomas et al., 1978). 
Mechanisms of CENU Resistance 
Tumor cells become resistant by: 1) decreasing 
cellular drug uptake and/or increasing drug efflux 
(Waud., 1987; Vendrik et al., 1992); 2) increasing 
intracellular detoxification of xenobiotics (Litterst, et 
al., 1985; Waxman, 1990; Teicher and Frei, 1991); 3) 
over-producing target proteins (Nunberg et al., 1978); 4) 
decreasing levels of bioactivating enzymes (Dulhanty, et 
al., 1989; Hoban et al., 1990); 5) increasing repair of 
macromolecular damage (Barrows, et al., 1987; Batist, et 
al., 1989; Bedford et al., 1988; Bodell, et al., 1988). 
The plasma membrane protein P-glycoprotein facilitates 
active efflux of a number of structurally unrelated 
chemotherapeutic agents (Vendrik, et al., 1992). 
Intracellular thiols such as glutathione and 
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metallothionine act as nucleophilic sinks for a number of 
DNA damaging agents (Teicher and Frei, 1991). Anti-
metabolite drug resistance is imparted by the over 
production of target proteins. A well characterized 
example of this type of mechanism is the amplification 
and over- expression of the dihydrof olate reductase gene 
in mediating methotrexate resistance (Nunberg et al., 
1978). The decreased bioactivation of the pro-drug 
mitomycin C appears to involve compromised microsomal 
function (Hoban et al., 1990). The mechanism of primary 
importance to this dissertation is the increased cellular 
capacity to repair macromolecular damage. The mediation 
of CENU resistance by the DNA repair protein MGMT and 
modulation of such resistance will be extensively 
discussed. Furthermore, several secondary mechanisms 
implicated in CENU resistance will also be discussed 
below. 
MGMT and CENU Resistance 
The CENU-induced DNA interstrand cross-link is formed 
via an 0 6 -chloroethylguanine with subsequent cyclization 
yielding 0 6 , N1 -ethanoguanine (Tong, et al., 1981, 1982) 
This monoadduct interacts with the complementary base 
cytosine and results in a guanine-cytosine DNA 
interstrand cross-link. Completion of cross-link 
formation occurs in approximately 6-10 hr (Kohn, 1977; 
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Erickson et al., 1980a; Brent, 1985). This protracted 
time course for cross-link formation allows the repair of 
cross-link precursors by the 22 kd MGMT protein and 
prevents the accumulation of the lethal lesions (Brent, 
1985a) . 
Tumor cell lines that prevent the formation of CENU-
induced DNA interstrand cross-links are resistant to CENU 
cytotoxicity (Erickson et al., 1980 a,b). This 
resistance phenotype correlates well with the ability of 
a cell line to reactivate MNNG-damaged adenovirus. The 
phenotypic proficiency or deficiency in the reactivation 
of damaged adenovirus is referred to as MEthylation 
Repair positive (MER+) or MEthylation Repair negative 
(MER-), respectively (Day et al., 1980a). The MER 
phenotype (Day et al., 1980b) is also related to 0 6 -
methylguanine repair capability, and this ability or 
inability is designated Methyl Excision positive (Mex+) or 
Methyl Excision negative (Mex-), respectively (Salker and 
Strauss, 1981). These data suggest that CENU resistance, 
cross-link formation, reactivation of MNNG-damaged 
adenovirus, and 0 6 -methylguanine repair are closely 
associated (Erickson, 1991) . 
The purified E. coli 0 6 -alkylguanine-DNA 
alkyltransferase prevents the formation of BCNU cross-
links in damaged M13mp9 DNA in vitro (Robbins et al., 
1983). This bacterial counterpart of MGMT quenchs cross-
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link formation when incubated with the damaged template 
immediately after drug removal. However, increasing the 
interval between BCNU treatment of DNA and protein 
incubation by several hours allows cross-link formation 
(Robbins et al., 1983). These data suggest that the 
alkyltransferase protein repairs cross-link precursors, 
however, once the cross-links are formed, the protein is 
no longer effective. Experiments using a variety of CENU 
damaged templates and the human alkyltransferase MGMT 
further substantiate these observations (Brent, 1984, 
1985a) . Cells with high levels of MGMT activity are more 
resistant to CENU cytotoxicity than cells with little or 
no MGMT activity (Brent et al., 1985b, Yarosh et al., 
1985; Robbins et al., 1983). 
The cross-link precursors 0 6 -chloroethylguanine and 
0 6 , N1 -ethanoguanine appear to be substrates for MGMT 
(Brent et al., 1985a; 1988; 1990). Interaction with the 
cyclized intermediate results in a covalent cross-linking 
of the MGMT protein to DNA via the N-1 position of 
guanine (Gonzaga et al., 1990). Repair of the 0 6 -
chloroethyl monoadduct, or the formation of the DNA-MGMT 
cross-link quenchs DNA interstrand cross-link formation 
(Brent et al., 1983a; 1988; 1990; Gonzaga et al., 1990). 
There appears to be no regeneration of the alkylated MGMT 
molecule and recovery of functional protein could not be 
distinguished from de nova synthesis (Yarosh et al., 
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1986) . The repair of 0 6 -alkylguanine by MGMT is 
stoichiometric; one MGMT molecule repairs one alkyl 
lesion from the 0-6 position of guanine (Pegg et al., 
1983). Studies exploiting this suicidal property of MGMT 
to induce a temporary MER- phenotype to CENU resistant 
cells will be elaborated below. 
Experiments introducing various MGMT complementary 
DNAs into Mer- cells demonstrated the direct 
cytoprotective effect of MGMT. Cytotoxicities of BCNU, 
ACNU, and chlorozotocin are markedly reduced by the 
transf ection of the MGMT or ada cDNAs into repair 
deficient cells (Ling-Ling et al., 1992; Hayakawa et al.; 
1992, Samson et al., 1986; Kataoka et al., 1986; Barrows 
et al. 1987) . 
Pegg et al. (1983, 1990, 1993) have proposed the 
following mechanism for the transfer of alkyl groups from 
the 0-6 position of guanine to MGMT. Based on 
comparative cDNA sequence analysis and site-directed 
mutagenesis studies, the active site in MGMT has been 
assigned putatively to the -Pro-Cys-His-Arg-Val- motif 
representing the amino acid residues 144-148 of the MGMT 
protein (Ling-Ling et al., 1992). Site directed mutation 
of the cys-145 residue to valine renders the protein 
inactive (Ling-Ling et al., 1992). The Cys-145 residue 
within peptide sequence appears to be the alkyl acceptor 
site within MGMT (Olsson and Lindahl, 1980; Mehta et al., 
20 
1981; Pegg et al., 1983; Ling-Ling et al., 1992). 
Mechanistically, the alkyl group transfer could be 
facilitated by the generation of a thiolate anion from 
the cysteine acceptor, and the adjacent arginine and 
histidine residues aid in the formation and stabilization 
of the anion. This thiolate anion could attack the alkyl 
group at the 0-6 position of guanine yielding the native 
guanine and the alkylated protein. This reaction does 
not require any other proteins or cofactors, and has a pH 
optimum of 7.8-8.5 (Pegg et al., 1983). The alkyl group 
transfer may be a bi-molecular displacement reaction 
resembling the first half of the ping-pong enzyme 
mechanism where a functional group is transferred from 
the substrate to the active site of the enzyme, resulting 
in a covalent linkage (Pegg, 1990). The isolation of an 
alkylcysteine residue from MGMT incubated with methylated 
DNA or BG provides strong evidence for this mechanism 
(Pegg et al., 1983, 1993). However, the exact molecular 
mechanism of this reaction remains to be deduced. Site 
directed mutagenesis studies indicate that the histidine 
and valine residues in the active site are not essential 
for repair of methylated DNA (Ling-Ling et al., 1992). 
Experiments examining substrate specificity and rate 
constants for these mutant MGMT proteins must be 
performed to clarify their role in the catalytic transfer 
(Pegg et al., 1993). 
Pharmacologic Depletion of MGMT and Reversal of CENU 
Resistance 
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Reversal of CENU resistance by DNA methylating agents. 
Methylating agent-induced 0 6 -methylguanine lesions in 
DNA appears to be important in mutagenesis, 
carcinogenesis, and cytotoxicity. This lesion in DNA is 
currently the most efficient substrate for MGMT with a 
second order rate constant of 0.02 x 10 8 mo1- 1 min- 1 (Pegg 
et al., 1984; Bhattacharyya et al., 1990). The 0 6 -
methylguanine lesions in DNA produced by methylating 
agents are repaired by MGMT and result in the 
inactivation of the protein (Brent, 1986) . Methylating 
agents are collectively referred to as indirect MGMT 
depleting agents because they must first react with DNA 
in order to provide a substrate for MGMT. 
The suicidal nature of MGMT-mediated repair of 0 6 -
methylguanine lesion has been exploited to enhance CENU 
cytotoxicity in resistant cells in vitro. Pre-treatment 
of resistant cells with MNNG results in the inactivation 
of MGMT, and thereby can potentially increase alkylating 
agent cytotoxicity (Waldstein et al., 1982). Pre-
treatment of the CENU resistant cell lines IMR-90 and HT-
29 with non-toxic doses of MNNG prior to CENU 
administration produces increased CNU-induced DNA 
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interstrand cross-links and cell killing (Zlotogorski and 
Erickson, 1983). Similarly, non-toxic doses of MNU, STZ 
and methyl methane sulfonate can also increase CNU cross-
link formation and cytotoxicity in HT-29 cells 
(Zlotogorski and Erickson, 1984; Erickson et al., 1988). 
In the same cell line, mitozolamide-induced cytotoxicity 
and cross-link formation are enhanced by MNNG or STZ pre-
treatment (Gibson and Erickson, 1985; Gibson et al., 
1986). Furthermore, a non-toxic dose of STZ (2.5 rnM) 
inhibits MGMT activity and increases cross-link formation 
and cytotoxicity in HT-29 cells (Futscher et al., 1989). 
Serial administration of temozolamide or dacarbazine and 
BCNU depletes MGMT and increases BCNU cytotoxicity in HT-
29 cells in vitro (Mitchell and Dolan, 1993). However, 
the administration of STZ, dacarbazine, or temozolamide 
prior to BCNU produces negligible MGMT inactivation and 
growth inhibition of colon carcinoma, medulloblastoma and 
glioblastoma xenografts (Mitchell and Dolan, 1993; 
Friedman et al., 1992). 
The in vitro effectiveness of the methylating agents 
in sensitizing CENU resistant cells prompted the phase 
I/phase II clinical testing of the combination of STZ and 
BCNU (Micetich et al., 1992; Panella, 1992; Willson, 
1992) The dose limiting toxicities of the combination 
include thrombocytopenia, transient hypophosphatemia, and 
proteinuria. Additionally, the maximally tolerated dose 
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of BCNU when combined with STZ is reduced by 50% 
(Micetich, et al., 1992). The intrinsic cytotoxic 
potential of STZ and the lack of tumor selective 
inactivation of MGMT may be responsible for the apparent 
exacerbation of BCNU toxicity (Willson, 1992; Micetich, 
et al., 1992). Therefore, the clinical use of STZ in the 
inactivation of MGMT and the reversal of BCNU resistance 
might be limited. Furthermore, the clinical use of 
methylating agents as MGMT depleting agents could 
increase the chance of secondary malignancies because 
MGMT plays a pivotal role in the prevention of MNU and 
MNNG induced mutagenesis and carcinogenesis (Dumenco et 
al., 1993; Nakatsuru, et al., 1993). 
Inactivation of MGMT and reversal of CENU resistance 
by guanine analogs. 
The guanine analogs which deplete MGMT include 0 6 -
methylguanine (MG) , 0 6 -benzylguanine (BG) , and a series of 
alkyl, halogenated and nucleoside derivatives of BG 
(Karran, 1985; Dolan et al., 1990b; Moschel et al., 
1992) . The free base MG was initially thought to deplete 
MGMT by serving as a misincorperated substrate within t-
RNA (Karran, 1985). However, the incorporation of the 
free base into nucleic acids is not necessary to deplete 
MGMT activity (Dolan et al., 1985). MG can produce 
substantial, albeit, incomplete depletion of MGMT 
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activity in HeLa cells by serving as a substrate for MGMT 
(Dolan et al., 1985). Incubation of 0 6 -methyl-[ 3H]-
guanine with HeLa cell extract containing MGMT results in 
stoichiometric repair suggesting that MG directly 
interacted with MGMT (Dolan et al., 1985). The rate of 
repair of MG is 10 7 times slower than when contained 
within double stranded DNA suggesting MG is a poor 
substrate for MGMT (Yarosh, 1986). Pre-treatment of 
several resistant cell lines with millimolar 
concentrations of MG for periods of 4 hr or longer 
results in 80% depletion of MGMT and 1-2 log potentiation 
of CNU, CCNU, meCCNU, HeCNU, and BCNU cytotoxicities in 
vitro (Dolan et al., 1986; Yarosh et al., 1986, Thielmann 
et al., 1987, Dempke et al., 1987). Additionally, MG can 
also deplete MGMT activity, increase BCNU and clomesone 
induced cytotoxicity and enhance DNA interstrand cross-
linking in HT-29 cells (Dolan et al., 1988). In contrast 
to its in vitro effectiveness, MG only partially 
inactivates MGMT and fails to inhibit the growth of HT-29 
xenografts implanted in nude mice when combined with BCNU 
(Dolan et al, 1989). This incomplete MGMT inactivation 
in tumor xenograf ts and rodent tissues requires extremely 
large doses of MG (Pegg, 1990). The low affinity of MG 
for MGMT, lack of in vivo enhancement of CENU 
cytotoxicity, and the limited solubility of MG are 
considerable difficulties for the clinical use of MG. 
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Based on the premise that a benzyl group could more 
readily participate in a bimolecular displacement 
reaction than a methyl group, Dolan et al. (1990 a,b) 
demonstrated that the free base 0 6 -benzylguanine (BG) was 
a potent, non-toxic, irreversible inactivator of MGMT. 
As little as 2 µM BG can completely ablate MGMT activity 
within 5 min in HT-29 extracts (Dolan et al., 1990 b). 
Incubation of [3H]-06 -benzylguanine with extracts 
containing MGMT results in the liberation of 
stoichiometric amounts of [3H]-guanine. Furthermore, the 
inactivation of MGMT leads to the formation of s-
benzylcysteine within the protein (Pegg et al., 1993). 
These data suggest that BG directly interacts with MGMT, 
serves as a substrate for alkyl transfer, and yields a 
native guanine and the benzylated protein. The second 
order rate constant for this reaction is 600 M- 1 s- 1 (Pegg 
et al., 1993). Evidence further suggests that 
benzylation of MGMT induces a conformational change in 
the protein which may stimulate rapid proteolytic 
digestion of the inactive protein (Pegg, et al., 1991) 
Site-directed mutagenesis studies suggest that the cys-
145 residue is the alkyl acceptor site and pro-140 is an 
integral component of the BG hydrophobic binding site 
within MGMT. This proline 140 residue is replaced by an 
alanine residue in the bacterial alkyltransferase ada and 
may be partially responsible for the differential 
26 
sensitivity of the two proteins to BG (Crone and Pegg, 
1993). In addition, the sequences in the divergent 28 
amino acid tail within MGMT appear to be involved in the 
BG binding site since the deletion of this tail reduces 
BG mediated inhibition of MGMT by 5 fold (Morgan et al., 
1993) . 
The inactivation of MGMT and reversal of CENU 
resistance by BG has been demonstrated in numerous tumor 
cell lines and xenografts. Treatment of HT-29 cells with 
micromolar doses of BG prior to clomesone, BCNU, CCNU, or 
chlorozotocin administration results in the potentiation 
of CENU cytotoxicity (Dolan et al., 1991). Pretreatment 
with BG also results in the induction of BCNU interstrand 
cross-links, reduction in colony formation, and 
significant inhibition of HT-29 and SF767 xenograft 
growth (Dolan et al, 1990a; Mitchell et al., 1992). The 
enhancement of ACNU cytotoxicity or the dose modification 
factor ( IC50 ACNU alone/IC50 BG+ACNU) is related to the 
functional MGMT content in a cell line or xenograft (Chen 
et al., 1993 a,b). The rank order of enhancement of BCNU 
cytotoxicity in several cell lines by BG appears to be a 
function of MGMT activity (Dolan et al., 1991; Chen et 
al., 1993 a,b). This phenomenon has been corroborated in 
vivo by Dolan et al. (1993 b) by testing the anti-tumor 
activity of the combination of BG+BCNU against four colon 
carcinoma xenografts with high, intermediate, and low 
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levels of MGMT activity. The effectiveness of this 
combination in vivo is further evidenced by the induction 
of partial and complete regression of medulloblastoma and 
glioblastoma tumors implanted subcutaneously, and 
intracranially (Friedman et al., 1992; Felker et al, 
1993). The modulation of BCNU resistance in vivo in a 
colon cancer xenograft (Vaco 6) has subsequently been 
accomplished by repeated administrations of BG (Gerson et 
al., 1993). In this study, tumor bearing animals were 
administered BG pre- and 2 hr post-BCNU treatment. The 
post-BCNU administration of BG may have inactivated 
nascent MGMT molecules which could have maximized the 
formation of DNA interstrand cross-links (Gerson et al., 
1993). The host toxicity of the combined use of a CENU 
and BG necessitates at least a 50% reduction in the dose 
of the CENU in many of these animal experiments. Data 
from histopathological examination of several rat tissues 
from BCNU and the combination of BG and BCNU treated 
rats, suggest that the dose-limiting determinants are due 
to gastrointestinal, splenic, and hematopoietic 
dysfunction (Dolan et al., 1993a). 
CENU resistance modulation has predominately operated 
on the premise that MGMT should be initially depleted, 
prior to CENU exposure, in order to sensitize resistant 
cells to CENU cytotoxicity. However, CENU-induced cross-
links continue to form for an extended period of 6-12 hr 
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after CENU removal (Erickson et al., 1980a). It is 
possible that any newly synthesized MGMT following a 
resistance modulator could conceivably react with a 
cross-link precursor and decrease the formation the 
lethal DNA interstrand cross-link. Therefore, in order 
to maximize cross-link formation and cytotoxicity, MGMT 
should be inactivated throughout the time course of 
cross-link formation. Experiments described within this 
dissertation address this hypothesis by determining 
whether extended depletion of MGMT after BG, STZ, and the 
combination of BG and STZ is indeed required to maximize 
BCNU cytotoxicity. 
Role of Glutathione in CENU resistance 
The majority of data strongly indicate that DNA 
interstrand cross-links are the predominant cytotoxic 
lesions and that MGMT plays a pivotal role in CENU 
resistance by preventing cross-link formation. However, 
several other mechanisms of CENU resistance have also 
been implicated. In four medulloblastoma cell lines, a 
relationship between cellular content of MGMT activity 
and BCNU cytotoxicity was not demonstrated (Silber, et 
al., 1992). Additionally, cells expressing MGMT could 
not be sensitized to BCNU cytotoxic effects by BG 
pretreatment (Silber, et al., 1992). In a subsequent 
study, a panel of eight human brain tumors with low to 
29 
high levels of MGMT activity were not appreciably 
sensitized to BCNU cytotoxicity by BG. The authors 
suggested that MGMT was not a primary determinant in 
predicting BCNU sensitivity in their cell lines and that 
in vivo BCNU resistance in brain tumors may be 
independent of MGMT content (Bobola et al., 1993) These 
data suggest that other mechanisms of CENU resistance may 
exist in MGMT expressing cell lines. A secondary 
mechanism of CENU resistance may involve the 
intracellular detoxification of CENU by glutathione 
(GSH) . 
Glutathione is present in mammalian cells at 
intracellular concentrations of 5-10 mM (Kosower and 
Kosower, 1978). This tripeptide (Glu-Cys-Gly) contains a 
strong nucleophilic thiol group within the cysteine 
residue that can act as a nucleophilic sink for numerous 
electrophiles such as free radicals, reactive oxygen 
species, and many other endogenous and exogenous 
compounds (Chesseud, 1979; Meister and Anderson, 1983). 
The xenobiotics which react with GSH include cisplatin 
and the DNA alkylating agents melphalan, BCNU, and 
nitrogen mustard (Moscow et al., 1989; Hantel., et al 
1991; Evans et al., 1987). Conjugation of these 
electrophiles with GSH convert them to non-toxic 
metabolites which are transported extracellularly and 
degraded by proteases (Bakke, 1990). The conjugation 
occurs both in enzymatic and non-enzymatic processes. 
The enzymatic process is mediated by a class of 
glutathione-S-transferases (GST) which may determine 
substrate specificity. 
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Treatment of cells with BCNU pre-incubated with GSH 
prior to cell exposure in vitro results in increased 
clonogenicity, decreased DNA interstrand cross-linking, 
and decreased the inhibition of DNA replication in a 
human glioblastoma cell line (Ali-Osman et al., 1989 
a,b). Ali-Osman et al. (1989a) suggested that the 
conjugation of GSH with the cross-link precursor 0 6 -
chloroethylguanine in DNA may result in the formation of 
1-(06 -deoxyguanosyl), 2-S-glutathionylethane. The 
formation of this conjugate may prevent the 
intramolecular rearrangement and subsequent reaction with 
the complementary base cytosine, and thereby quench 
cross-link formation (Ali-Osman, 1989a) . The Pi and Mu 
isozymes of GST mediate the conjugation of BCNU with GSH 
followed by subsequent denitrosation of BCNU. The Pi 
class of isozymes appears to be responsible for 
detoxification of BCNU in human brain tumor cells (Ali-
Osman et al., 1990), whereas the Mu isozymes mediate the 
conjugation of GSH and BCNU in rat brain tumor cells 
(Smith et al., 1989). The significance of GSH in BCNU 
resistance is unclear since many of the studies which 
addressed the role of GSH and BCNU resistance did not 
assess the relative contribution of such resistance 
conferred by MGMT. 
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Sensitization of the HT-29 cell line, a MER+ colon 
carcinoma cell line, to BCNU cytotoxicity by depleting 
GSH has been attempted by Hantel et al. (1990). This 
cell line contains 14-15 fold greater GSH and GST 
activity than its MER- counterpart BE. Reduction in HT-29 
GSH content by more than 80% with buthionine sulfoximine 
(BSO) (a competitive inhibitor of the rate limiting 
enzyme in GSH biosynthesis, gamma-gultamyl synthase) does 
not modify BCNU cytotoxicity. HT-29 cells contain high 
levels of MGMT activity, and without MGMT depletion, the 
significance of GSH depletion in BCNU resistance in MER+ 
cells would be difficult to assess. Because MGMT is 
clearly an important mechanism of resistance in MER+ 
cells, any secondary consequence of GSH depletion would 
have been masked by MGMT repair function. In order to 
partially resolve this issue, an experiment 
simultaneously targeting MGMT and GSH depletion is 
described in Appendix I. 
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CHAPTER III 
PROLONGED DEPLETION OF 0 6 -METHYLGUANINE DNA 
METHYLTRANSFERASE ACTIVITY (MGMT) FOLLOWING EXPOSURE TO 
0 6 -BENZYLGUANINE WITH OR WITHOUT STREPTOZOTOCIN ENHANCES 
1,3 BIS(2-CHLOROETHYL)-1 NITROSOUREA SENSITIVITY IN VITRO 
Pretreatment of resistant cells with MGMT depleting 
agents prior to CENU exposure successfully inactivates 
MGMT, enhances DNA cross-link formation, and increases 
cytotoxicity (Zlotogorski and Erickson, 1984; Dolan et 
al., 1986; Dolan et al., 1990 a,b). However, recent 
observations suggested that maximal sensitization of CENU 
resistant cells might require a more extended depletion 
of MGMT following BCNU (Dolan et al., 1990; Gerson et 
al., 1993). The observation that the DNA interstrand 
cross-link precursor 0 6 , N1 ethanoguanine is stable for 
greater than 8 hr following CENU removal, suggests the 
potential for cross-linking exists for extended periods 
(Brent, 1985b). Indeed, cross-links produced by several 
CENU continue to form for 6-12 hr post-drug exposure and 
persist for at least 24 hr in the MGMT deficient cell 
lines (Ewig and Kohn, 1977; Erickson et al., 1980a). 
Furthermore, when BG is employed as the BCNU resistance 
modulator, optimal enhancement of BCNU cytotoxicity 
requires pre- and post-BCNU exposure of cells to BG 
(Dolan et al., 1990; Gerson et al., 1993). The 
administration of BG following BCNU treatment may 
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inactivate nascent MGMT molecules. Additionally, this 
inactivation could prevent the repair of the stable 
cross-link precursors (Gerson et al., 1993). Therefore, 
inactivation of MGMT for prolonged periods throughout the 
time-course of cross-link formation would be expected to 
maximize cross-link formation and cytotoxicity in MGMT 
expressing cells. However, no attempt has been made to 
compare the enhancement of CENU cytotoxicity produced by 
a single dose of BG with repeated administration of BG, 
and thereby substantiate the aforementioned conclusions. 
Therefore, the experiments described in this chapter 
attempt to determine whether extended depletion of MGMT 
activity is required for maximal enhancement of BCNU 
cytotoxicity by BG or STZ in resistant cells. 
In this chapter two pretreatment protocols were used 
to examine whether extended depletion of MGMT was 
required to maximize BCNU cytotoxicity. The enhancement 
of BCNU cytotoxicity and the recovery of MGMT activity 
were measured following BG (10-100 µM) and the 
combination of BG (10 µM) and STZ (1.0 mM) in vitro. In 
the three drug combination of BG+STZ+BCNU, BG can deplete 
MGMT allowing a greater number of STZ induced 0 6 -
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methylguanine lesions to form which can deplete MGMT for 
an extended period. The combination of BG+STZ produced a 
more extended depletion of MGMT for 24 hr and a greater 
enhancement of BCNU cytotoxicity than when BG or STZ were 
used alone. If the mechanism by which STZ increased 
BG+BCNU cytotoxicity was by producing a more prolonged 
depletion of MGMT, then higher doses of BG (10-100 µM) 
which can deplete MGMT for 24 hr should also produce a 
comparable enhancement of BCNU cytotoxicity. A 100 µM 
dose of BG produced complete inactivation of MGMT for 
greater than 24 hr and the greatest enhancement of BCNU 
cytotoxicity. The studies suggest that the greatest BCNU 
sensitization is reached when MGMT activity was depleted 
prior to, and for at least 24 hours following BCNU 
administration. Moreover, these data suggest that the 
design of clinical strategies targeting MGMT inactivation 
should consider prolonged inhibition of MGMT activity to 
increase the likelihood of anti-tumor responses. 
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Materials and Methods 
Cell Culture 
HT-29 cells were cultured in Eagle's minimum essential 
medium, supplemented with 10% bovine calf serum, 62.5 mM 
HEPES buffer, 1 mM glutamine, 1 mM sodium pyruvate, 1 X 
vitamin B12, 1 X non-essential amino acids (Hazelton) and 
0.05 mg/ml gentamicin. Cells were maintained in log 
phase at 37°C in 95% air, 5% C02 atmosphere. 
Colony Formation Assay 
HT-29 cells were seeded at 150, 300, 1000, 3000, and 
10,000 cells per T-25 mm3 flask and incubated for 11-14 hr 
to allow for complete attachment. When testing the 
cytotoxicity of the various combinations of BG, STZ, and 
BCNU, triplicate flasks were individually treated with 
BG, STZ and/or BCNU. BG, STZ, and BCNU were dissolved in 
dimethylsulfoxide, 0.9% NaCl, and 95% ethanol, 
respectively. The administration of dimethylsulfoxide 
(1.0%) for 3 hr, or ethanol (1.0%) for 1 hr did not 
produce greater than 2-3 % inhibition of colony 
formation. Cells were cumulatively exposed to BG for 3 
hr, STZ for 2 hr, and BCNU for 1 hr. In assessing the 
cytotoxicity induced by BG+BCNU, cells were treated with 
BG (10-lOOµM) for 2 hr prior to a 1 hr exposure to BCNU. 
Following treatment, drug containing medium was aspirated 
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and replaced with fresh medium. After 9-10 days, cells 
were fixed in 100 % methanol, stained with a buffer 
containing 2.31 mg/ml methylene blue, 2.5 rnM Na
2
HP04 , l.33 
mM KH2 P04 , and colonies were counted. The survival values 
plotted for the combinations of BG+BCNU, STZ+BCNU, and 
BG+STZ+BCNU were normalized to BG, STZ and BG+STZ alone 
induced cell killing. Survival curves show the mean and 
the standard deviation of three or more independent 
experiments. A minimum of triplicate determination of 
cytotoxicity were made within each experiment. 
Measurement of MGMT activity 
The assay for MGMT activity Used in this study was 
developed by Wu et. al. (1987) and subsequently modified 
in our laboratory (Futscher et al., 1989; Pieper et al., 
1991) . Cultured cells were resuspended at a 
concentration of approximately 3x10 7 cells/ml in assay 
buffer (50 mM Tris pH 8, 1 mM DTT, 1 rnM EDTA, 5% 
glycerol), quickly frozen in dry ice, and stored at -80°C 
for subsequent measurement of MGMT activity. The effects 
of freezing and thawing of cells on MGMT activity will be 
discussed below. 
Due to exonuclease activity of the Klenow fragment of 
DNA polymerase, the radiolabelling of the 0 6 -methylguanine 
containing oligomer used in this study was catalyzed by 
the Stoffel fragment of the Taq DNA polymerase. The 18 
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base pair oligomer containing an 0 6 -methylguanine lesion 
was radiolabelled by filling in the 3' recessed end with 
thymidine 5'- [a- 32 P] triphosphate (TTP) (Amersham, 
Arlington Heights, IL). 20 pmol of probe were incubated 
with 10 units of Stoffel Taq DNA polymerase (Perkin 
Elmer/Cetus, Norwalk, CT), 50 µCi of TTP (specific 
activity 3000 Ci/mmol), 1.5 mM MgC1 2 , lX Taq buffer at 
42°C for 1 hr. The labeling reaction was terminated with 
sequential extraction with phenol:chloroform:isoamyl 
alcohol (PCI) and chloroform:isoamyl alcohol (CI). 
Subsequently the DNA was precipitated in 70% ethanol, 
73.0 mM sodium acetate and 20 µg oft-RNA. 
In measuring MGMT activity, the radiolabelled oligomer 
was incubated with 10 µg of total cellular protein (2 hr, 
37°), PCI extracted, digested with Pvu II (1 hr, 37°) 
(Gibco BRL, Gaithersburg, MD), and electrophoresed on a 
20% denaturing polyacrylamide gel. The extent of 
restriction enzyme cleavage of the radiolabelled 18 mer 
to an 8 mer by Pvu II is directly proportional to MGMT 
activity (Wu et al., 1987). The radioactivity was 
quantitated on a Betagen Betascope 603 blot analyzer. 
The % probe cleaved = (CPMs 8 mer/ CPMs 18 mer + CPMs 8 
mer) X 100. Measurement of MGMT activity following 
treatment with BG and STZ was normalized to untreated 
control values. Each data point represented the mean and 
the standard deviation of three independent experiments. 
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Freezing and thawing of cells did not result in 
appreciable loss of MGMT activity. Incubation of the 
radiolabelled 18 mer with 25 µg of extracts freshly 
prepared HT-29 extract resulted in 76.4 +/- 2.16 % probe 
cleaved following Pvu II digestion. Incubation of 25 µg 
frozen cell extract for 24 hr at -80°C with the 0 6 -
methylguanine containing DNA resulted in 76.0 +/- 4.2 % 
probe cleaved following Pvu II digestion. 
Sl nuclease analysis of steady state MGMT mRNA levels 
Labeling of the MGMT Sl probe 
A PCR-generated MGMT cDNA was subcloned into the pGEM 
-3Z f- vector (Promega, Madison, Wi) and designated pMGMT 
(Pieper et al., 1990). pMGMT (10 µg) was digested with 
10 units of Hinl I (Promega), and electrophoresed on a 1% 
agarose gel. The 2.4 kb Hinl I fragment was excised from 
the gel and purified by centrifugation through silanized 
glass wool at 12,000 X g. The filtrate was extracted 
with phenol, and PCI, and then precipitated with ethanol. 
The purified DNA was incubated with 5 units of Klenow DNA 
polymerase (Promega) and 10 µCi of deoxycytidine 5'-[a-
32P] triphosphate (Amersham) (6000 Ci/mmol) at room 
temperature for 15 min. The labelling reaction was 
terminated by extracting once with PCI, once with CI 
extraction, followed by precipitation with ethanol. This 
probe protects 570 nucleotides of MGMT mRNA. 
39 
Sl nuclease protection assay 
Excess labelled MGMT Sl probe was incubated with 40µg 
of cytoplasmic RNA in 0.4 M NaCl, 40 mM 1,4-
piperazinediethanesulfonic acid (pH 6.8), 2 mM EDTA and 
80% formamide. The hybridization mixture was denatured 
at 68°C for 15 min, immediately transferred to a 53°C 
bath, and incubated >16 hr. Subsequently, the nucleic 
acid was digested with 400 U of Sl nuclease (Boehoringer 
Mannheim, Philadelphia, PA) at 37°C for 1 hr, extracted 
with PCI, precipitated with ethanol, and electrophoresed 
on a 4% denaturing polyacrylamide gel. The gel was 
fixed in 10% acetic acid for 15 min, soaked in water for 
15 min, dried at 80°c for 1 hr, and autoradiographed. 
The probe was determined to be at least 100 fold in 
excess of MGMT mRNA represented within 40 µg of HT-29 RNA 
by comparing the intensity on the autoradiograph of 1:100 
dilution of the radiolabelled probe alone to the 
intensity of 100 fold greater amount of probe incubated 
with 40 µg of RNA. As determined by densitometric 
analysis, the intensity of the probe alone control was 
11.70 % greater in intensity than that was measured in 40 
µg of RNA isolated from untreated HT-29 cell (Figure 
3.6). Therefore, the probe used in these experiments was 
at least 100 fold in excess. 
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Results 
Dose dependent depletion of MGMT activity by BG. 
To measure MGMT activity, a 32 P-end-labeled 18 base 
pair oligomer containing an 0 6 -methylguanine lesion in the 
Pvu II restriction site was incubated with 10 µg of whole 
cell sonicate protein from control and BG treated HT-29 
cells. Repair of 0 6 -methylguanine by MGMT allowed Pvu II 
cleavage of the oligomer to an 8 bp 32P-labeled fragment. 
The percentage of restriction enzyme cleavage was 
directly proportional to MGMT activity (Wu et al., 1987). 
The 10 µg of HT-29 cell extract was used in the 
measurement of MGMT activity to maximize the sensitivity 
of the assay. This amount of protein was at the 
saturation threshold of the assay (Appendix II) . The 
experiments described in this dissertation were designed 
to measure decreases and not increases in MGMT activity 
following drug treatment. Therefore, small decreases in 
MGMT activity could reliably be measured at the maximal 
sensitivity of the assay in HT-29 cells using this 
protein concentration. Exposure of HT-29 cells to BG 
(0.05-25 µM) for 3 hr depleted MGMT activity in a dose 
dependent fashion with an approximate dose for 50% 
inhibition of 150 nM (Figure 3.1). To insure maximal 
inhibition of MGMT activity, a 10 µM dose of BG was 
-- --:I • 
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Figure 3.1: 
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The effect of 0 6 -benzylguanine (BG) on MGMT activity in 
HT-29 cells. 
Cells were exposed for 3 hrs with 0.05-25 µM BG. 0 6 -
methylguanine containing probe was incubated with O µg 
protein (lane 1), O µg protein and digested with Pvu II 
(lane 2), O µg protein and digested with Hae III (lane 
3), 10 µg of total cellular protein from untreated (lane 
4) or BG treated HT-29 cells (lanes 5-14) and digested 
with Pvu II. Extent of Pvu II digestion is proportional 
to MGMT activity. 
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chosen for BCNU sensitization studies. 
Comparison of the cytotoxicity induced by the combination 
of BG+BCNU, STZ+BCNU, BG+STZ+BCNU. 
Figure 3.2 illustrates the enhancement of BCNU 
cytotoxicity by BG alone, STZ alone, or the combination 
of BG+STZ. BG alone, STZ alone, or combination of BG 
(lOµM) and the three doses of STZ were non-cytotoxic to 
HT-29 cells (Table 3.1). Therefore, the observed 
enhancement of BCNU cytotoxicity by the various 
pretreatment regimen was indeed synergistic. Treatment 
of HT-29 cells with 10 µM BG for 2 hr prior to a 1 hr 
exposure to BCNU resulted in an increase in the toxicity 
of lOOµM BCNU by approximately 0.5 log (Figure 3.2). 
Administration of STZ at the non-toxic doses of 0.25-1.0 
mM for 2 hr prior to BCNU exposure did not appreciably 
modify BCNU cytotoxicity. However, the addition of STZ 
at the non-toxic doses of 0.25-1.0 mM to BG+BCNU 
increased cytotoxicity in a dose dependent manner. HT-29 
cells were exposed to BG (10 µM) for 1 hr, followed by 
STZ [0.25 mM (A), 0.5 mM (B), 1.0 mM (C)] for 1 hr, and 
subsequently to a 1 hr exposure to BCNU. These cells 
received a 3 hr, 2 hr, 1 hr, exposure to BG, STZ, and 
BCNU, respectively. The addition of non-cytotoxic doses 
of STZ (0.25, 0.5, 1.0 mM) to BG+BCNU resulted in 
approximately 0.5-1.0 additional log enhancement of 
BG+BCNU cytotoxicity. The enhancement of BCNU 
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HT-29 cells were treated with BCNU alone, or STZ (0.25, 0.50, 1.0 mM) + BCNU, or 
BG (10 µM)+BCNU, or BG (10 µM) + STZ (0.25, 0.50, 1.0 mM) + BCNU. Cells were 
exposed to BG for 2 hrs and STZ for 1 hr prior to a 1 hr exposure to BCNU. 
Identical survival curves for BCNU alone and BG+BCNU are reproduced in panels A, B 
and c. Panel A, B, and C, illustrate the enhancement of BG+BCNU cytotoxicity by 
STZ at 0.25, 0.5, and 1.0 mM respectively. Each data point represents the mean 
and the standard deviation of three or more independent experiments. However, the 
data point depicting the cytotoxicity produced by BG(lO µM) + STZ (1 mM) + BCNU 
(100 µM) represents the mean of two independent experiments. 
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Table 3.1: 
Cell survival• following the various pretreatment regimens 
used to enhance BCNU cytotoxicity 
% Survival 
BG (10.0 µM) b 92.10 +/- 6.50 
STZ (0.25 mM)b 108.2 +/- 11. 6 
STZ (0.50 mM) b 112.2 +/- 17.2 
STZ (1. 00 mM) b 107.9 +/- 12.7 
BG (10.0 µM) + 
STZ (0.25 mM) c 107.3 +/- 6.80 
BG (10. 0 µM) + 
STZ (0.50 mM) c 104.1 +/- 1.10 
BG (10.0 µM) + 
STZ (1. 00 mM) c 102.1 +/- 11. 9 
a The survival values reported in this table indicate the 
percentage of cells surviving +/- the standard deviation 
after treatment with the various regimens. b The 
cytotoxicity scores for STZ, BG alone are normalized to 
untreated control values. c The combination cytotoxicity 
values are normalized to scores obtained with BG alone, 
and therefore reflect the cytotoxicity produced by STZ 
when combined with BG. 
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cytotoxicities, as reflected in the doses of BCNU 
required to kill 90 % of seeded cells (IC90), is 
illustrated in Table 3.2. The addition of STZ at a dose 
of 1.0 mM to the BG+BCNU regimen resulted in 1.86 fold 
reduction in IC90 dose of BCNU. 
Resynthesis of MGMT activity following treatment with BG, 
STZ, and BG+STZ. 
When STZ was used as the sole modulator of CENU 
resistance, the formation of BCNU induced interstrand 
cross-links and the enhancement of cytotoxicity were 
related to the regeneration rate of MGMT activity 
(Erickson et al., 1988; Pieper et al 1991). As the 
interval between STZ and CENU was increased, MGMT 
activity recovered, and the potentiation of cross-link 
formation and cytotoxicity decreased. These data suggest 
that resynthesis of MGMT following STZ might be an 
important determinant in CENU resistance. Based on these 
observations, I hypothesized that the mechanism by which 
STZ enhanced the toxicity of BG+BCNU was by producing a 
more extended depletion of MGMT. Figure 3.3 illustrates 
the regeneration of MGMT activity following treatment of 
cells with BG (10 µM), or STZ (1.0 mM), or BG+STZ. 
Adhering to the treatment strategy used in the survival 
assays, HT-29 cells were exposed to BG for 3 hr and STZ 
for 2 hr. 
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Table 3.2: 
The IC90 dosesa of BCNU after treatment with BG, STZ, and 
the combination of BG+STZ 
BCNU alone 
BCNU + 
BG ( 10. 0 µM) 
BCNU + 
BG (10.0 µM) + 
STZ (0.25 mM) 
BCNU + 
BG (10.0 µM) + 
STZ (0.50 mM) 
BCNU + 
BG ( 1 0 . 0 µM) + 
STZ (1.00 mM) 
> 150 µM 
117.5 µM 
92.5 µM 
82.5 µM 
63.1 µM 
a The concentration of BCNU required to inhibit the growth 
of 90 % of seeded cells. The values depicted in this 
table were extrapolated from the data illustrated in 
figure 3.2. 
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Figure 3.3: 
MGMT activity in HT-29 cells following treatment with BG 
alone (10 µM), or STZ alone (1.0 mM), or BG (10 µM) + STZ 
(1.0 mM). 
Following exposure of cells to BG alone for 3 hrs, STZ 
alone for 2 hrs or the combination of BG + STZ, drug 
containing medium was aspirated and replaced with fresh 
media. Cells were harvested O hr, 3 hr, 6 hr, 12 hr, 24 
hr following drug removal. Panel A depicts MGMT activity 
in HT-29 cells following drug treatment. Quantitation of 
the results within panel A is shown in panel B. MGMT 
activity is expressed as a percentage of activity 
measured in untreated HT-29 cells. Each data point 
represents the mean and the standard deviation of three 
independent experiments. 
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Subsequently, the drug containing medium was 
aspirated, replaced with fresh media, and the cells were 
allowed to recover for 0, 3, 6, 12, 24 hr following drug 
removal. At each time point, cells were harvested to 
assess MGMT activity (Figure 3.3 A,B) and mRNA levels 
(Figure 3.6). Cells exposed to 1 mM STZ alone gradually 
recovered MGMT activity reaching near control levels by 
24 hr. In contrast, cells exposed to BG (10 µM) 
recovered approximately 15% of control activity within 6 
hr, and essentially remained at that level through 24 hr. 
Upon sequenced administration of BG and STZ, MGMT 
activity was completely inhibited essentially for 24 hr. 
Because the prolonged depletion of MGMT activity produced 
by BG+STZ through 24 hr resulted in greater enhancement 
of BCNU cytotoxicity than BG or STZ alone, it is 
suggested that prolonged depletion of MGMT activity is 
required to maximize BCNU cytotoxicity. 
Effect of increased doses of BG on BCNU cytotoxicity and 
recovery of MGMT activity 
To further explore whether extended depletion of MGMT 
is an important determinant in BCNU resistance, the 
recovery of MGMT activity and the potentiation of BCNU 
cytotoxicity by BG at doses greater than 10 µM were 
examined (Figure 3.4). If the extended depletion 
provided by the addition of STZ to the 10 µM dose of BG 
was indeed responsible for the greater cytotoxicity, then 
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Cells were treated with 10-100 µM BG for 2 hr prior to a 
1 hr exposure to BCNU. Drug containing medium was 
removed and replaced with fresh medium. Each data point 
represents the mean and the standard deviation of results 
from three independent experiments. However, the data 
point depicting the cytotoxicity produced by the BG 
(lOOµM) + BCNU (lOOµM) represents the mean of two 
independent experiments. 
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Figure 3.5: 
MGMT activity in HT-29 cells following treatment with BG 
(10-lOOµM) . 
Cells were treated with BG (10-100 µM) for 3 hr, 
replaced with fresh medium, and harvested at 0, 3, 6, 9, 
12, 24, and 48 hr after drug treatment. Panel A 
illustrates the MGMT activity in HT-29 cells following 
treatment with 0, 10, 25, 50, and 100 µM BG. Within each 
quadrant of panel A, lanes 1 through 7 represent MGMT 
activity at 0, 3, 6, 9, 12, 24, 48 hr following BG 
removal. Panel B represents quantitation of results 
within panels A, where MGMT activity is expressed as a 
percentage of MGMT activity within untreated HT-29 cells. 
Each data point represents the mean and the standard 
deviation of three independent experiments. 
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increased doses of BG which deplete MGMT for an extended 
period should produce comparable cytotoxicity. When HT-29 
cells were pretreated for 2 hr with 10-100 µM BG and 
subsequently challenged with BCNU, the potentiation of 
BCNU-induced cell kill increased in a dose dependent 
fashion (Figure 3.4). When the recovery of MGMT activity 
was measured following exposure to 10-100 µM BG, MGMT 
activity was also inhibited in a dose and time dependent 
fashion (Figure 3.5). At a 100 µM dose of BG, which 
completely depleted MGMT for 48 hr, greater than 3 logs 
of BCNU induced cell kill was observed. These results 
further supported the hypothesis that the extended 
depletion of MGMT activity was required for maximal 
enhancement of BCNU cytotoxicity. 
Effect of prolonged depletion of MGMT activity on steady 
state MGMT mRNA levels 
The steady state MGMT mRNA levels did not change 
following treatment with STZ (Pieper et al., 1991). To 
examine whether prolonged depletion of MGMT activity 
affected the steady state MGMT mRNA levels, expression of 
the MGMT message was measured using an Sl nuclease 
protection assay. As illustrated in figure 3.6, when 
cells were treated with STZ alone, BG alone, or the 
combination which depleted MGMT activity for up to 24 hr, 
there was no change in steady state mRNA levels. 
Densitometric analysis indicated that there was no more 
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than 1.30 % difference between any of the treatment 
groups and untreated control. Additionally, in HT-29 
cells depleted of MGMT activity for 48 hr with lOOµM BG, 
MGMT mRNA levels were unaltered (Figure 3.7). 
Quantitation of these results demonstrated that there was 
no greater than 14.3 % difference between measurements 
made in control and BG treated cells. 
-BG STZ · BG •STZ 
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Figure 3.6: 
Steady state mRNA levels following BG (10 µM), STZ (1 mM) or BG+STZ in HT-29 
cells. 
Cells collected in the MGMT regeneration experiments were split for the 
determination of MGMT activity and mRNA levels. 40 µg of cytoplasmic RNA from 
treated and untreated HT-29 cells were hybridized with excess probe and digested 
with Sl nuclease resulting in the correct 570 nucleotide protection of the MGMT 
mRNA. Lane designations proceeding from left to right are the following: lane 1, 
molecular size markers; lane 2, 1:100 dilution of undigested Sl probe; lane 3, 
level of MGMT mRNA in untreated cells; lanes 4-8, mRNA levels in BG (10 µM) 
treated cells, lanes 9-13, mRNA levels in cells treated with STZ (1 mM), lanes 14-
18, mRNA levels in cells treated with the combination of BG+STZ. The numbers 
indicated above lanes 4-18 depict the time of cell harvest in hours following drug 
removal. 
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Figure 3.7: 
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Steady state MGMT mRNA levels following a 100 µM ·dose of 
BG 
Lane 1 represents the levels of mRNA in untreated HT-29 
cells. Lanes 2-8 represents the level of MGMT mRNA from 
cells treated with BG at a dose of 100 µM for 3 hr and 
harvested at the indicated times (in hours) . 
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However, this recovery could be prevented for 24 hr by 
the addition of a 1.0 mM dose of STZ, or for 48 hr by 
increasing the dose of BG to 100 µM. The prolonged 
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inhibition of MGMT produced by either STZ addition, or by 
BG (lOOµM) resulted in a greater enhancement of BCNU 
cytotoxicity than the lOµM dose of BG. These 
observations may be explained in the following fashion. 
When STZ was added to BG (lOµM), the STZ induced 0 6 -
methylguanine lesions persisted in DNA providing 
substrates for MGMT, and resulted in the repair-mediated 
inactivation of the protein for prolonged periods. By 
increasing the dose of BG to lOOµM, the residual amounts 
of BG remaining within cells, after drug removal, 
probably provided ample concentrations of the compound to 
inactivate MGMT for extended periods. As a consequence of 
this prolonged inactivation, the repair of the CENU-
induced chloroethyl monoadducts was prevented, resulting 
in increased levels of interstrand cross-links, and BCNU 
cytotoxicity. Collectively, the data suggest that 
extended depletion of MGMT activity is an important 
determinant in the reversal of CENU resistance, and that 
chemotherapeutic regimens targeting the inactivation of 
MGMT activity should be optimized such that MGMT activity 
is depleted for prolonged periods following CENU 
administration. 
Pieper et al. (1991) observed that the resynthesis of 
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MGMT activity after treatment with STZ was not 
accompanied by changes in steady state MGMT mRNA levels. 
In order to ascertain whether a sustained inhibition of 
MGMT activity would induce a compensatory change in mRNA 
levels, a sensitive Sl nuclease protection assay was 
developed to measure changes in mRNA levels. There was 
no change in steady state mRNA levels when MGMT activity 
was depleted for 24 hr with the combination of BG+STZ, or 
for 48 hr with lOOµM BG. These data demonstrated that 
during the period of prolonged depletion of MGMT 
activity, the expression of MGMT mRNA was not inducible. 
The observed regeneration of MGMT activity following STZ 
or BG treatment was probably the result of a slow nascent 
translation of steady state MGMT mRNA because MGMT was 
not reactivated after alkyl transfer (Yarosh et al., 
1986), and because MGMT repletion was dependent on RNA 
and protein synthesis (Yarosh et al., 1986; Gerson, et 
al., 1988). 
Additionally, STZ mediated reversal of CENU 
resistance necessitated a 2.5 mM dose of STZ prior to 
BCNU administration in vitro (Futscher et al., 1989). 
Because 2.5-10 fold lower doses of STZ (0.25 mM-1.0 mM) 
when combined with BG+BCNU effectively sensitized 
resistant cells in vitro, a clinical regimen using 
reduced doses of STZ in conjunction with BG+BCNU might 
attenuate the clinical toxicity observed in the STZ+BCNU 
clinical trial (Micetich et al., 1992). 
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If BG were to be 
used in combination with STZ, then a greater and 
prolonged inhibition of MGMT activity could be achieved. 
Moreover, the combined use of BG and STZ as cooperative 
modulators of CENU resistance could increase the 
possibility of an anti-tumor response compared to the use 
of either agent alone. The conclusions made in this 
chapter are further tested in the following chapter where 
the enhancement of BCNU cytotoxicity is examined under 
conditions of complete inhibition, partial or complete 
recovery of MGMT activity by 24 hr. 
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CHAPTER IV 
EXTENDED DEPLETION OF 0 6 -METHYLGUANINE DNA 
METHYLTRANSFERASE ACTIVITY FOLLOWING 0 6 -BENZYL-2'-
DEOXYGUANOSINE, OR 0 6 -BENZYLGUANINE COMBINED WITH 
STREPTOZOTOCIN TREATMENT ENHANCES 1,3 BIS{2-CHLOROETHYL)-
l-NITROSOUREA CYTOTOXICITY 
In the previous chapter, cells recovered only 10-15% 
of control activity by 6 hr following treatment with a 10 
µM dose of BG. Increasing the dose of BG from 10 to 100 
µM, or combining BG (lOµM) with STZ prevented this 
recovery and produced a greater enhancement of BCNU 
cytotoxicity. From these data, it was suggested that 
extended depletion of MGMT was required to maximally 
enhance BCNU cytotoxicity in resistant cells. However, 
one may question whether the inhibition of only an 
additional 10-15% of control MGMT activity for 24 hr by 
the combination of BG+STZ can indeed explain the greater 
enhancement of BCNU cytotoxicity. Therefore, a repeated 
wash protocol was developed to in order to more 
definitively determine whether the regenerative rate of 
MGMT activity is related to the enhancement of BCNU 
cytotoxicity by BG or STZ. The regeneration of MGMT 
62 
activity in the VACO 6 cell line after BG administration 
was dramatically altered by washing of cells with serum 
containing media (Gerson et al., 1993). Washed cells 
rapidly recovered to control levels of MGMT activity, 
whereas unwashed cells remained depleted (Gerson et al., 
1993). In this chapter experiments will be presented 
which use the repeated washing of cells to modulate the 
recovery rate of MGMT activity, and to evaluate the 
potentiation of BCNU cytotoxicity induced by regimens 
which provide complete inhibition, partial or complete 
recovery of MGMT activity by 24 hr. The regenerative 
rates of MGMT activity and the enhancement of BCNU 
cytotoxicity with and without washing were measured 
following BG, STZ, 0 6 -benzyl 2'-deoxyguanosine (dBG), and 
the combinations of BG+STZ and dBG+STZ. 
The recovery of MGMT after treatment with nucleoside 
derivative of BG, dBG, was studied because it was 
anticipated that this compound could potentially be 
phosphorylated, trapped within the cells, unaffected by 
washing, and continue to deplete MGMT for an extended 
period. However, as the studies presented in this 
chapter demonstrate, this compound behaves similar to BG 
in terms of MGMT inactivation and the potentiation of 
BCNU cytotoxicity. The data in this chapter further 
confirm that extended deletion of MGMT is required for 
maximal enhancement of BCNU cytotoxicity. 
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Materials and Methods 
Colony Formation Assay 
HT-29 cells were seeded at densities ranging from 150-
100, 000 cells per T-75 mm3 flask and incubated for 12 hr 
to allow for complete attachment. Cells were 
cumulatively exposed to BG or dBG for 3 hr, STZ for 2 hr, 
and BCNU for 1 hr. Following treatment, drug containing 
medium was aspirated, replaced with an equal volume of 
fresh medium, and then cells were allowed to recover for 
9-10 days. Alternatively, the cells were repeatedly 
washed with an equal volume of serum containing medium at 
37°C. A single wash cycle consisted of the following 
manipulations: 1) Medium from each flask was aspirated 
and replaced with fresh medium; 2) The flasks were gently 
tumbled three times. This process was repeated four 
times. After the final wash, cells were incubated for 9-
10 days, colony formation was assessed as described in 
the previous chapter. When testing the cytotoxicity of 
the combinations of BG+BCNU, dBG+BCNU, STZ+BCNU, BCNU 
induced cell kill was normalized to BG, dBG, STZ 
controls, respectively. The cytotoxicity produced by the 
various pretreatment regimens is illustrated in Table 
4.1. STZ, BG, dBG as single agents were not toxic to HT-
29 cells. However, the combinations of BG+STZ or dBG+STZ 
were mildly toxic. In assessing the cytotoxicity of the 
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Table 4.1: 
Survivala following various pretreatment regimens used to 
enhance BCNU cytotoxicity 
% Survival 
Without washing With wash 
STZ (2. 5 mM) b 90.06 +/- 10.8 91.52 +/- 10.6 
BG (100 µM) b 93.30 +/- 6.80 90.30 +/- 6.00 
dBG (1. 0 mM) b 98.90 +/- 1. 80 92.46 +/- 14.8 
BG (100 µM) + 
STZ (2. 5 mM) c 68.80 +/- 5.40 77.70 +/- 6.80 
dBG (1. 0 mM) + 
STZ (2. 5 mM) c 41.36 +/- 19.3 87.6 +/- 21. 6 
a The survival values reported in this table indicate the 
percentage of cells surviving +/- the standard deviation 
after treatment with the various regimens. b The survival 
scores for STZ, BG, or dBG alone were normalized to 
untreated control values. c The survival values for the 
combination of BG+STZ, or dBG+STZ were normalized to 
scored obtained when cells were treated with BG or dBG 
alone, and therefore reflect the cytotoxicity produced by 
STZ when combined with BG or dBG. 
combinations of BG+STZ+BCNU and dBG+STZ+BCNU, the 
cytotoxicity produced by these combinations was 
normalized to the cell killing produced by BG+STZ and 
dBG+STZ, respectively. Therefore, the survival values 
reflected the synergistic enhancement of BCNU 
cytotoxicity by the various pre-treatment regimens. 
Survival histograms show the mean and the standard 
deviation of at least three independent experiments. 
Measurement of MGMT activity 
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The protocol utilized in these experiments was similar 
to that described in chapter 3 except for one 
modification. In measuring MGMT activity, the 
radiolabelled 0 6 -methylguanine containing oligomer was 
incubated with 10 µg of total cellular protein at 37°C 
for 2 hr, digested with 40µg proteinase K (in the 
presence of 1.0 % sodium dodecyl sulfate) for 1 hr at 
45°C. The proteinase K digestion was added to increase 
the recovery of radioactivity. After protein extraction, 
the DNA was digested with Pvu II (Gibco BRL, 
Gaithersburg, MD), and electrophoresed on a 20% 
denaturing polyacrylamide gel. The extent of restriction 
enzyme cleavage of the radiolabelled 18 mer to an 8 mer 
by Pvu II was directly proportional to MGMT activity (Wu 
et al., 1987). The radioactivity was quantitated on a 
Betagen Betascope 603 blot analyzer. The % probe cleaved 
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= (CPMs 8 mer/ CPMs 18 mer + CPMs 8 mer) X 100. 
Measurement of MGMT activity following treatment with BG, 
dBG and/or STZ was normalized to untreated control 
values. 
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Results 
Effects of the combination of BG+STZ on the recovery of 
MGMT activity and potentiation of BCNU cytotoxicity. 
Figure 4.1 illustrates the repletion of MGMT activity 
in HT-29 cells following treatment with BG, STZ or the 
combination of BG+STZ. Consistent with the observations 
made in the VACO 6 cell line, the rate of repletion of 
MGMT activity following BG (100 µM) treatment increased 
upon repeated washing. Unwashed cells exhibited complete 
depletion of MGMT activity for 24 hr. In contrast, 
washed cells gradually recovered MGMT activity and 
reached near control levels by 24 hr. The repletion 
profile of MGMT activity following STZ treatment was 
unaffected by washing. STZ at a dose of 2.5 mM completely 
depleted MGMT activity for 12 hr after drug removal, and 
cells gradually recovered to approximately 30% of control 
activity by 24 hr. When cells were treated with BG and 
STZ in a sequential manner, the inactivation of MGMT 
activity was complete for 24 hr, irrespective of washing. 
These data suggested that when cells were depleted of 
MGMT with BG, prior to STZ administration, a greater 
number of STZ induced 0 6 -methylguanine lesions persisted 
and continued to inactivate nascent MGMT molecules for 
extended periods. 
The striking differences in the repletion profile of 
MGMT activity illustrated in Figure 4.1 predict dramatic 
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Figure 4.1: 
Differential recovery of MGMT activity following BG, STZ, 
or the combination of BG and STZ. 
HT-29 cells were exposed to BG (100 µM), STZ (2.5 mM) 
alone, or sequentially with the combination. Following 
drug treatment, some treated cells were washed as 
described in the "Materials and Methods" section. The 
cells were harvested and analyzed for MGMT activity at 
the indicated times after drug treatment with or without 
washing. Points, mean +/- SD of three independent 
experiments. 
69 
differences in the potentiation of BCNU cytotoxicity if 
extended depletion of MGMT activity is required for 
maximal enhancement of BCNU cytotoxicity. The rank order 
of the potentiation of BCNU cytotoxicity should inversely 
follow the repletion rate of MGMT activity. Those 
regimens producing the most prolonged inhibition of MGMT 
activity would be expected to produce the greatest 
cytotoxicity. 
Figure 4.2 illustrates the potentiation of BCNU 
cytotoxicity by BG, STZ, and the combination of BG+STZ 
with and without washing. The combination of BG (100 µM) 
+ BCNU (100 µM) without a wash produced approximately two 
to three logs of synergistic cell kill. However, cells 
exposed to the identical regimen and washed after BCNU 
exposure were dramatically less sensitive to the drug. 
This treatment produced less than one log of BCNU (100 
µM) synergistic cell kill. The sequential administration 
of STZ followed by BCNU (100 µM) produced approximately 2 
logs of synergistic cell kill. STZ mediated potentiation 
of BCNU cytotoxicity, similar to its repletion profile, 
was unaffected by washing. The combination of BG (100 
µM) + STZ (2.5 mM) + BCNU (100 µM) produced 3-4 logs of 
synergistic cell kill and this cytotoxicity was not 
appreciably affected by washing. These data demonstrate 
that extended depletion of MGMT activity is required for 
maximal enhancement of BCNU cytotoxicity because the pre 
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Cells were sequentially exposed to BG and BCNU at a 2 hr 
interval, STZ and BCNU or BG,STZ and BCNU at 1 hr 
intervals with the indicated doses. The treatment and 
wash protocols are detailed in the "Materials and 
Methods" section. The survival histograms depict the 
mean +/- SD of values obtained from three independent 
experiments. 
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treatment regimens which produced the slowest recovery 
rate produced the greatest cytotoxicity. 
Effects of the combination of dBG+STZ on the recovery of 
MGMT activity and the potentiation of BCNU cytotoxicity. 
To further test the hypothesis that extended depletion 
of MGMT activity was required for optimal reversal of 
BCNU resistance, the repletion of MGMT activity and 
potentiation of BCNU cytotoxicity by the nucleoside 
derivative of BG, dBG was examined. This compound has 10 
fold lower affinity for MGMT (Moschel et al., 1992). 
Figure 4.3 illustrates the repletion profile of dBG and 
BG at their respective IC100 doses (i.e. the dose 
producing complete inactivation in the oligonucleotide 
restriction assay) . Unwashed HT-29 cells recovered 
approximately 15% of control activity by 6 hr and 
essentially remain at that level for 12 hr following 
treatment with BG or dBG. However, in a profile similar 
to BG, the rate of repletion of MGMT activity following 
dBG treatment increased with repeated washing. Washed 
cells recovered approximately 60 % of control activity by 
12 hr. These data suggested that dBG similar to BG can be 
readily washed out of cells. 
When cells were treated with 0.1-1.0 mM dBG for 2 hr 
prior to BCNU administration without a wash, BCNU 
cytotoxicity increased in a dose dependent manner (Figure 
-Q ... ..... = Q 
Figure 4.3: 
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Comparative repletion of MGMT activity in HT-29 cells treated with BG and dBG. 
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8 "' 
IC100 doses of BG or dBG (lOµM and lOOµM, respectively) were administered to cells for 3 
hr and cells were harvested at the indicated times after drug treatment. 0 6 -
methylguanine containing probe was incubated with 10 µg of total cellular protein from 
untreated (lane 1), BG treated and unwashed (lanes 2-4), BG treated and washed (lanes 5-
7), dBG treated and unwashed (lanes 8-10), dBG treated and washed (lanes 11-13) HT-29 
cells. Extent of Pvu II cleavage of the 18 nucleotide fragment to an 8 nucleotide 
fragment is directly proportional to MGMT activity. The wash protocol is described in 
the "materials and methods". 
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Figure 4.4: 
Potentiation of BCNU cytotoxicity by dBG 
Cells were pretreated with dBG (0.1-1.0 mM) for 2 hr 
prior to a 1 hr exposure to various doses of BCNU. 
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After BCNU treatment, drug containing medium was 
aspirated, replaced with an equal volume of fresh medium, 
and colony formation was assessed after 10 days. Points, 
mean and SD of survival values measured in 3 or more 
replicate flasks. 
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4.4). This potentiation profile of BCNU cytotoxicity by 
dBG was extremely similar to BG (10-100 µM) mediated 
enhancement described in the previous chapter. This 
observation was consistent with the 10 fold lower 
affinity of dBG than BG for MGMT. In order to enhance 
BCNU cytotoxicity comparable to that produced by BG, 10 
fold greater doses of dBG were required. Measurement of 
the repletion kinetics of MGMT activity following dBG 
(0.1-1.0 mM) treatment (without a wash) revealed a modest 
dose and time dependent inhibition of MGMT activity 
(Figure 4.5). The 1.0 mM dose of dBG produced sustained 
inhibition of MGMT activity for 24 hr and the greatest 
BCNU cytotoxicity. These data suggested that extended 
depletion of MGMT following dBG treatment is also 
important in maximizing BCNU cytotoxicity. However, the 
activity measured in this experiment was extremely small. 
Therefore, this hypothesis was further tested by using 
dBG in a series of MGMT repletion and BCNU potentiation 
experiments with washes. Figure 4.6 illustrates the 
recovery of MGMT activity following 1.0 mM dBG alone and 
in combination with STZ with and without washes. dBG 
alone without a wash completely inactivated MGMT for 24 
hr. Upon repeated washing, the rate of recovery of MGMT 
activity increased dramatically. As previously shown, 
the repletion of MGMT activity following STZ was 
unaffected by washes. The combination of dBG+STZ 
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MGMT activity in HT-29 cells following treatment with dBG 
(100-1000 µ,M). 
Cells were treated with BG (100-1000 µM) for 3 hr, 
replaced with fresh medium, and harvested at 0, 3, 6, 12, 
and 24 hr after drug treatment. These data are from a 
single experiment. 
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Figure 4.6: 
Differential recovery of MGMT activity following dBG, 
STZ, and the combination of dBG and STZ. 
HT-29 cells were administered dBG (1.0 mM) for 3 hr, STZ 
(2.5 mM) for 2 hr or the combination. Following drug 
treatment, media was removed, replaced with fresh media 
or repeatedly washed as described in the "Materials and 
Methods". Points represent the mean+/- standard 
deviation of two independent experiments. 
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produced sustained inhibition of MGMT activity 
essentially for 24 hr, irrespective of washes. 
Examination of the potentiation of BCNU cytotoxicity by 
dBG with or without washes revealed the pattern of 
reversal of BCNU resistance was very similar to that seen 
with BG (Figure 4.7). The combination of dBG (1.0 mM) + 
BCNU (100 µM) without a wash produced approximately 3 
logs of synergistic cell kill. Repeated washing of cells 
drastically increased the recovery rate of MGMT activity 
and decreased BCNU cytotoxicity. When this recovery was 
prevented for 24 hr by the addition of STZ, the 
combination produced three to four logs of synergistic 
cytotoxicity at a 100 µM dose of BCNU. These data 
further demonstrated the importance of prolonged 
depletion of MGMT activity in CENU resistance modulation. 
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Differential potentiation of BCNU cytotoxicity by dBG, 
STZ or the combination of dBG+STZ with or without washes. 
The protocol utilized is identical to that described in 
figure 4.2. The points represent the mean+/- SD of 
three independent experiments. 
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Discussion 
The data presented within this chapter further confirm 
that extended depletion of MGMT following BG, dBG, and 
STZ was required to maximize BCNU in vitro. The data 
showed that pretreatment regimens producing the most 
extended depletion of MGMT activity for 24 hr produced 
the greatest enhancement of BCNU cytotoxicity. The 
recovery rate of MGMT activity following dBG or BG was 
modulated by repeated washing of cells. BG and dBG, 
without washing, produced complete depletion of MGMT 
activity for 24 hr and potentiated BCNU cytotoxicity by 
about 3 logs. The prolonged depletion resulted 
presumably from residual BG or dBG remaining within 
cells. However, washing of cells following BG or dBG 
administration increased the repletion rate of MGMT; 
cells recovered to control levels of MGMT by 24 hr. 
Under these conditions, the enhancement of BCNU 
cytotoxicity was markedly diminished to less than one log 
of synergistic cell kill. STZ was combined with BG or 
dBG to prevent this post-wash recovery of MGMT, and to 
restore non-wash sensitivity. The post-wash recovery of 
MGMT activity following BG or dBG administration was 
inhibited for 24 hr by the addition of STZ. The 
sequential exposure of BG followed by STZ, or dBG 
followed by STZ, produced sustained inhibition of MGMT 
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activity for 24 hr, irrespective of washing. The 
combination of BG+STZ+BCNU or dBG+STZ+BCNU produced 
greater than 3 to 4 logs of synergistic cell kill with or 
without washing. 
The repletion profiles of the direct MGMT depleting 
agents BG and dBG markedly differed from that of STZ 
after repeated washing of cells. BG and dBG produced 
sustained inhibition of MGMT for 24 hr without washing, 
whereas with washing MGMT gradually recovered to control 
levels by 24 hr. Because BG and dBG are lipophilic 
molecules, repeated presentation of drug free medium to 
cells probably facilitated the removal of the compounds 
via passive diffusion. With the resultant decrease in 
intracellular concentrations of the free bases, MGMT 
activity recovered at a faster rate. In contrast, the 
recovery rate of MGMT following STZ treatment was 
unaffected by washing. This result is consistent with 
the mechanism by which STZ depletes MGMT. STZ-induced 0 6 -
methylguanine lesions in DNA facilitate the repair-
mediated inactivation of MGMT (Brent, 1986). Washing of 
cells would not be expected to change the intracellular 
concentration of this substrate, and therefore not affect 
the regenerative rate of MGMT. 
Dolan et al. (1990a; 1991) suggested that optimal 
reversal of BCNU resistance required cellular 
administration of BG pre- and post-BCNU exposure because 
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the presentation of BG to cells following BCNU 
facilitated the inactivation of nascent MGMT molecules 
(Yarosh, et al., 1986; Gerson et al., 1988) and thereby 
increased BCNU sensitivity. Consistent with this notion, 
Gerson et al., (1993) suggested that prolonged depletion 
of MGMT prevented the repair of the stable, cross-link 
precursor 0 6 , N1 ethanoguanine. Prevention of this repair 
by BG post-BCNU administration could have increased the 
accumulation of the cytotoxic DNA interstrand cross-links 
(Gerson et al., 1993). 
In BG or dBG treated and washed cells, MGMT activity 
recovered and presumably repaired any persistent cross-
link precursors, and thereby prevented the accumulation 
of DNA interstrand cross-links. This precursor repair 
was probably attenuated by the addition of STZ to BG, or 
dBG. The sequential administration of a guanine analog 
and STZ probably allowed a greater number of STZ induced 
0 6 -methylguanine lesions in DNA to persist, providing 
substrates which continued to deplete MGMT activity for 
24 hr. This greater extended depletion of MGMT probably 
allowed an increased number of BCNU cross-links which 
were responsible for greater cytotoxicity. 
The kinetics of BCNU cross-link formation and removal 
in CENU resistant cell lines depleted of MGMT have not 
been measured, but the frequency of BCNU induced cross-
links did indeed increase when resistant cells were 
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initially depleted of MGMT by STZ or BG (Futscher et al., 
1989; Mitchell et al., 1992). However, these were static 
determinations made at the estimated times of maximal 
cross-linking (6 or 14 hr after drug treatment) . In an 
MGMT deficient cell line, BCNU, CCNU, CNU and 
chlorozotocin induced cross-links continued to form for 
6-12 hr after drug removal (Erickson et al., 1980a). The 
steady state level of cross-links beyond 12 hr could be 
due to continual formation of interstrand cross-links and 
repair by perhaps an excision repair mechanism (Swinnen 
et al., 1991). The potential for continuous cross-link 
formation was suggested by the remarkable stability of 
the cross-link precursor 0 6 , N1 ethanoguanine; this 
intermediate was stable in DNA for greater than 8 hr 
after drug removal (Brent et al., 1987). Extended 
depletion of MGMT might be required to maximize DNA 
interstrand cross-links and cytotoxicity in CENU 
resistant cells because MGMT reacted with this precursor, 
resulted in the formation of an MGMT-DNA cross-link 
instead of a DNA interstrand cross-link. This hypothesis 
might be tested by examining the kinetics of cross-link 
formation under conditions of complete inhibition, 
partial, and complete recovery of MGMT activity by 24 hr 
in CENU resistant cells. 
If extended depletion of MGMT was the sole determinant 
for maximizing BCNU cytotoxicity, then all regimens which 
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provided complete inhibition of MGMT for 24 hr should 
have produced comparable cytotoxicities. However, BG and 
BG+STZ completely inhibited MGMT for 24 hr, but the 
combination of BG+STZ+BCNU produced at least 1 log 
greater cytotoxicity than BG+BCNU in an unwashed 
situation. Likewise, the combination of dBG+STZ 
potentiated BCNU cytotoxicity greater than dBG alone. 
The greater cytotoxicity produced by the addition of STZ 
to BG+BCNU or dBG+BCNU regimen may be attributed to the 
cytotoxic effects of STZ induced 0 6 -methylguanine lesions. 
Day et al (1987) proposed that the 0 6 -methylguanine lesion 
could trigger lethality by activating a type of mismatch 
repair acting on the distortion in DNA created by the 
inappropriate base pairing of 0 6 -methylguanine : cytosine. 
Once this mismatch is detected, several bases in the 
undamaged strand of DNA are incised and resynthesized 
(Day et al., 1987). The infidelity of the repair 
polymerase could generate another mismatch across the 0 6 -
methylguanine lesion (Day et al., 1987). The creation of 
another mismatch may result in futile cycle of mismatch 
repair, depleting nucleotide pools, and resulting in the 
cytostatic effects of methylating agents (Day et al., 
1987; Kat et al., 1993). 
Kaina et al. (1991) demonstrated that the transfection 
of the MGMT or ada complementary DNAs protected CHO cells 
from the mutagenic, clastogenic and cytotoxic effects of 
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MNNG, HeCNU, and the STZ parent compound MNU. These data 
indicate that 0 6 -methylguanine is indeed a cytotoxic 
lesion and MGMT plays a pivotal role in preventing the 
toxic effects mediated by this lesion. The following 
remarks are offered to explain the greater cytotoxicity 
induced by the three-drug combinations (BG+STZ+BCNU and 
dBG+STZ+BCNU) than any two drug regimen. When MGMT was 
initially depleted with BG or dBG, a greater number of 
STZ induced 0 6 -methylguanine lesions would be expected to 
form, act in concert with the toxic lesions produced by 
BCNU, and thereby produce a greater potentiation of BCNU 
cytotoxicity. However, the cytotoxicities of the three-
drug combinations were normalized to cytotoxicities 
induced by the combination of BG+STZ or dBG+STZ. 
Whatever intrinsic lethality offered by the addition of 
STZ would have been accounted for in the normalization 
process. One may speculate that the cytostatic response 
mediated by the 0 6 -methylguanine lesion was greater in the 
presence of BCNU induced DNA damage than in its absence. 
If this speculation is correct, the three-drug 
combination would be expected to produce greater 
cytotoxicity than the non-STZ containing regimens. 
Further experiments are clearly required to resolve this 
issue. 
Because the combined administration of the direct MGMT 
depleting agents, dBG or BG, and the indirect depleting 
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agent, STZ, sensitized HT-29 cells to BCNU cytotoxicity 
to a greater degree than modulation with a single agent, 
the combined clinical testing of resistance modulators 
with different modes of action might be justified. In 
chapter three, it was observed that the combination of 
BG+STZ at 10 fold lower doses than used in this study, 
effectively sensitized BCNU resistant cells. A clinical 
regimen utilizing a low dose of BG followed by a low dose 
STZ might decrease the clinical toxicities observed in 
the recent STZ+BCNU clinical trials (Micetich et al., 
1992). This protocol may produce a more efficient 
depletion of MGMT than the use of BG or STZ alone. If 
ample plasma concentrations of BG cannot be achieved to 
produce sustained inhibition in tumors exhibiting high 
levels of MGMT due to the limited solubility of the 
compound, then repeated administration of BG, or the 
addition of STZ to a BG+BCNU regimen might be necessary. 
The addition of STZ to a BG+BCNU regimen could result in 
extended depletion of MGMT, and the STZ-induced DNA 
damage could increase the tumor cell lesion burden, 
thereby increasing the possibility of anti-tumor 
responses. In the following chapter, the enhancement of 
BCNU cytotoxicity by the combination of BG+STZ is further 
tested in an in vivo anti-tumor model in order to 
determine the potential clinical utility of the 
sequential administration of BG, STZ, and BCNU. 
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CHAPTER V 
ANTI-NEOPLASTIC ACTIVITY OF SEQUENCED ADMINISTRATION OF 
BG, STZ, AND BCNU IN VITRO AND IN VIVO 
In the previous chapters, the combined administration 
of BG+STZ produced an extended depletion of MGMT for 24 
hr and a greater enhancement of BCNU cytotoxicity than 
either BG or STZ. Based on these in vitro observations, 
the clinical testing of this combination was recommended. 
In order to further justify this recommendation, the 
effectiveness of extended depletion of MGMT for 24 hr on 
the enhancement of BCNU anti-tumor activity was examined 
in vivo with the combination of BG and STZ. The 
experiments presented in this chapter used the resistant 
human glioblastoma SF767 cells grown in culture, and as 
subcutaneous xenografts in nude mice. The feasibility of 
the potential clinical use of the three-combination was 
tested in vivo with the subcutaneous xenograft model 
because this anti-tumor model more reliably predicts the 
clinical utility of novel chemotherapeutic regimens than 
in vitro cytotoxicity assays. 
SF767 astrocytoma cell line was selected on basis of 
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the rationale developed by Mitchell et al. (1992). These 
investigators suggested that, because rodent tissue 
generally contained lower MGMT activity than their human 
equivalents, the use of a human xenograft with comparable 
levels of MGMT to host tissues may be more predictive of 
the clinical effectiveness of a potential 
chemotherapeutic regimen. Therefore, the SF767 cell 
line, which contains approximately equivalent MGMT 
activity to mouse liver (Mitchell et al., 1992; Figure 
5.5), was used for the in vivo testing of the combination 
of BG+STZ+BCNU. 
Furthermore, the growth rate of SF767 xenografts was 
significantly inhibited by i.p. administration of BG (80 
mg/kg) followed by BCNU (20 mg/kg) without appreciable 
animal toxicity (i.e. in terms of animal death and nadir 
in weight loss) (Mitchell et al., 1992). STZ was added 
to this treatment protocol in order to examine whether 
the combination of BG+STZ would produce a more extended 
depletion of MGMT activity and a greater enhancement of 
BCNU anti-tumor activity than that obtained with BG in 
cultured SF767 cells and xenografts. 
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Materials and Methods 
Colony Formation Assay 
The human glioma cell line, SF767, was kindly provided 
by The Brain Tumor Research Center, University of 
California at San Francisco. SF767 cells were cultured in 
Eagle's minimum essential medium, supplemented with 10% 
bovine calf serum, 62.5 mM HEPES buffer, 1 mM glutamine, 
1 mM sodium pyruvate, 1 X vitamin B12, 1 X non-essential 
amino acids, and 0.05 mg/ml gentamicin. Cells were 
maintained in log phase at 37°C in 95% air, 5% C02 
atmosphere. The cytotoxicity assay used in this chapter 
was identical to that described in chapter 3. 
Animal studies 
Female NIH Swiss nude mice and NIH Swiss normal mice 
were purchased from Frederick Cancer Research and 
Development Center (Frederick, MD) . Animals were housed 
in a sterile environment and provided with food and water 
ad libitum. The nude mice were subcutaneously injected 
in the flank region with 7-10 x 10 6 SF767 cells. In tumor 
growth studies, animals were randomized and treated with 
various regimens when tumor volumes reached 30-112 mm3 • 
Animal weights and tumor volumes were measured twice per 
week. Additionally, animals were euthanized when tumor 
89 
exceeded 1500 mm3 • Tumor volumes were calculated using 
the formula: Length X Width2 X 0.53. In the MGMT 
repletion studies, tumor volumes ranged from 200 to 400 
mm3 at the time of treatment. BG, STZ, and BCNU were 
dissolved in 10% cremophor EL, normal saline, and 10% 
ethanol/90% normal saline, respectively. At various 
times following drug exposure, mice were euthanized via 
cervical dislocation. The tumors and organs were 
dissected, quickly frozen in liquid nitrogen, and stored 
at -80°C for subsequent MGMT analysis. 
Measurement of MGMT activity 
The preparation of MGMT extracts and measurement of 
MGMT activity from cultured cells have been previously 
described in chapters four and five. In preparing MGMT 
extracts from SF767 xenografts and organs, the dissected 
tumors and organs which had been frozen at -80°C were 
thawed and homogenized for 30 sec in approximately 3 ml/g 
wet tissue weight of homogenizing buffer containing 50 mM 
Tris, 5 mM DTT, 0.1 mM EDTA, pH 8 with an OMNI 
International 1000 tissue homogenizer. The homogenate 
was centrifuged for 5 min at 12,000X g at 4°C. The cell 
pellet was reconstituted to approximately 1 ml/g of 
original wet tissue weight, homogenized for 15 sec and 
sonicated for an additional 30 sec. Both supernatants 
were combined and centrifuged at 12,000 X g at 4°C for 30 
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min. Total cellular protein concentration of the 
supernatant was quantitated utilizing the Bradford micro 
protein assay (Bio Rad, Richmond, CA.). To measure MGMT 
activity, a 32P-labeled 18 base pair oligomer containing 
an 0 6 -methylguanine lesion in the Pvu II restriction site 
was incubated with lOµg or 25µg of whole cell sonicate 
protein in the homogenizing buffer for 2 hr. After the 
incubation, the protein was digested with 40µg of 
proteinase K in the presence of 1% sodium dodecyl sulfate 
for 1 hr at 45°C. The DNA was purified using a single 
PCI extraction and ethanol precipitation. The DNA was 
subsequently digested with 10 units of Pvu II, 
electrophoresed on a 20% denaturing polyacrylamide gel 
and autoradiographed. Repair of 0 6 -methylguanine by MGMT 
allows Pvu II cleavage of the oligomer to an 8 base pair 
32P-labeled fragment. The percentage of restriction 
enzyme cleavage is directly proportional to MGMT 
activity. The radioactivity was quantitated using the 
Betagen betascope 603 blot analyzer. % probe cleaved= 
(CPMs of 8 mer/CPMs of 18 mer+ CPMs of 8 mer) x 100. 
The values of MGMT activity measured after drug treatment 
was normalized to untreated control values. 
Results 
Inactivation of MGMT activity and potentiation of BCNU 
cytotoxicity by the following pretreatment regimens in 
SF767 cells; BG, STZ, and the combination of BG+STZ 
The human astrocytoma cell line SF767 contains 
appreciable levels of MGMT and is consequently highly 
resistant to the cytotoxic effects of CENUs (Dolan et 
al., 1991). The repletion kinetics of MGMT activity 
following treatment with BG (lOµM), STZ (0.5mM), and the 
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combination of BG+STZ is illustrated in Figure 5.1. MGMT 
activity was completely inactivated immediately following 
BG exposure. Thereafter, cells recovered no greater than 
15% of control MGMT activity through 24 hr. Following 
STZ treatment, MGMT was inactivated by greater than 90% 
of control activity at O hr, and recovered to 
approximately 60% of control activity by 24 hr. However, 
sequential administration of BG and STZ produced near 
complete inactivation of MGMT activity through 24 hr. 
The combination of BG+STZ produced a greater and a more 
extended inhibition of MGMT activity than either agent 
alone. 
Figure 5.2 illustrates the potentiation of BCNU 
cytotoxicity by the various pretreatment regimens. BG, 
STZ, or the combination of BG+STZ were essentially non 
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Figure 5.1: 
Inactivation and recovery of MGMT activity in SF767 cells 
in vitro. 
SF767 cells were treated with BG (10 µM) for three hours, 
STZ (0.5 rnM) for two hours or the combination. After the 
three hours the drug containing medium was removed and 
replaced with fresh medium. The illustrated times refer 
to the time of cell harvest following drug removal. MGMT 
activity is expressed as a percentage of activity in 
untreated SF767 cells. Points represent the mean +/- SD 
of three independent experiments. 
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Figure 5.2: 
Comparison of the cytotoxicity induced by BG+BCNU, 
STZ+BCNU, or BG+STZ+BCNU in vitro. 
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SF767 cells were treated with BCNU (50-100 µM) alone, or 
STZ (0.50 mM) + BCNU (50-100 µM), or BG (10 µM) + BCNU 
(50-100 µM), or BG (10 µM) + STZ (0.50 mM) + BCNU (50-100 
µM) . Cells were exposed to BG for 2 hr and STZ for 1 hr 
prior to a 1 hr exposure to BCNU. Each data point 
represents the mean +/- SD of three independent 
experiments. 
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Table 5.1: 
Survivala following the various pretreatment regimens used 
to enhance BCNU cytotoxicity in SF767 cells 
% Survival 
BG (10.0 µM) b 96.60 +/- 0.63 
STZ (0.50 mM)b 87.37 +/- 5.44 
BG (10.0 µM) + 
STZ (0.50 mM) c 87.19 +/- 6.24 
a The survival values reported in this table indicate the 
percentage of cells surviving +/- the standard deviation 
after treatment with the various regimens. b The 
cytotoxicity scores for STZ, BG alone are normalized to 
untreated control values. c The combination cytotoxicity 
values are normalized to scores obtained with BG alone, 
and therefore reflect the cytotoxicity produced by STZ 
when combined with BG. 
toxic at the doses used in these studies (Table 5.1). 
Cytotoxicities of BG+BCNU, STZ+BCNU, BG+STZ+BCNU were 
normalized to BG, STZ, or BG+STZ cytotoxicity. 
Therefore, the enhancement of BCNU cytotoxicity 
illustrated in Figure 5.2 by the different pretreatment 
regimens was synergistic. The combinations of STZ+BCNU, 
BG+BCNU, BG+STZ+BCNU at 100 µM dose of BCNU potentiated 
cell killing by approximately 0.5, 1.0 and 2.0 logs, 
respectively. The enhancement of BCNU cytotoxicity as 
reflected in the decrease in the IC90 dose of BCNU, is 
illustrated in Table 5.2. The addition of STZ at a dose 
of 0.5 mM to the BG+BCNU regimen resulted in a 22.9 % 
reduction in the IC90 dose of BCNU. The combination of 
BG+STZ, which produced extended depletion of MGMT 
produced the greatest sensitization of SF767 cells to 
BCNU cytotoxicity. These observations were consistent 
with the determinations made in HT-29 cells in that the 
combination of BG+STZ produced a more extended depletion 
of MGMT and a greater enhancement of BCNU cytotoxicity 
than BG or STZ alone. These data demonstrate that the 
requirement of extended depletion of MGMT in maximizing 
BCNU cytotoxicity is not restricted to HT-29 cells. 
95 
96 
Table 5.2: 
The IC90 doses• of BCNU when SF767 cells were treated with 
the various pretreatment regimens 
BCNU alone > 100 µM 
BCNU + 
STZ (0.5 mM) > 100 µM 
BCNU + 
BG (10.0 µM) 87.5 µM 
BCNU + 
BG ( 10. 0 µM) + 
STZ (0.5 mM) 67.7 µM 
a The concentration of BCNU required to reduce survival of 
the seeded cells by 90%. The values depicted in this 
table were extrapolated from the data illustrated in 
figure 5.2. 
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Effects of the combination of BG+STZ on the inactivation 
of MGMT activity and the enhancement of BCNU anti-tumor 
activity in vivo. 
The following series of experiments examined whether 
the addition of STZ to the BG+BCNU regimen would produce 
extended depletion of MGMT activity for 24 hr and greater 
inhibition of tumor growth, or produce tumor regression 
when compared to the combination of BG+BCNU alone. 
Preliminary acute toxicity studies using female NIH Swiss 
regular mice were performed to determine the maximally 
tolerated dose of STZ in the three drug combination of 
BG+STZ+BCNU (Table 5.3). Animals were administered the 
combinations of BG+BCNU or BG+STZ+BCNU i.p. The dose BG 
was fixed at 80 mg/kg. Animal were treated with BG 
followed by BCNU at 15 or 20 mg/kg. Alternatively, 
animals were injected with BG followed by STZ (25-200 
mg/kg) followed by the BCNU. The maximally tolerated 
doses of the three drug combination were inferred to be 
BG at 80 mg/kg, STZ at 100 mg/kg, and BCNU at 15 mg/kg 
because these doses produced minimal weight loss and no 
animal deaths, and because any further increases in the 
dose of STZ, and/or BCNU resulted in animal deaths. 
Therefore, the 80 mg/kg dose of BG and the 100 mg/kg dose 
of STZ were used in MGMT repletion experiments and BCNU 
anti-tumor experiments in female nude mice bearing SF767 
xenografts. Animals were injected with BG, STZ, or the 
Table 5.3: 
Toxicities of BG+BCNU and BG+STZ+BCNU combinations 
in normal NIH swiss female mice 
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Mice were sequentially administered BG, STZ, and/or BCNU 
i.p. at one hour intervals. Animal weights were measured 
twice weekly for 28 days. 
Combination (mg/kg) 
BG (80)+ BCNU (15) 
BG ( 80) + BCNU (15)+ STZ 
BG ( 80) + BCNU ( 15) + STZ 
BG ( 80) + BCNU ( 15) + STZ 
BG ( 80) + BCNU ( 15) + STZ 
BG ( 80) + BCNU ( 2 0) 
BG ( 80) + BCNU (20) + STZ 
BG ( 80) + BCNU (20) + STZ 
BG ( 80) + BCNU (20) + STZ 
( 25) 
( 5 0) 
( 100) 
( 2 00) 
(25) 
( 5 0) 
( 100) 
Mean maximum 
wt loss (%) 
7.50 
13.0 
11. 0 
5.90 
10.5 
15.6 
13.4 
18.1 
22.8 
# of animal 
deaths a 
0/4 
1/4 
0/4 
0/4 
4/12b 
2/4 
1/4 
2/4 
3/4 
aNumber of animal deaths/number of animals treated. These 
data reflected the number of spontaneous deaths and the 
number of animals sacrificed following 20-25% reduction 
in total body weight. 
bSurvival through 14 days. 
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Repletion of MGMT activity in SF767 xenografts following 
treatment with BG, STZ, or BG+STZ. 
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Mice carrying SF767 xenografts were administered 80 mg/kg 
BG one hour prior to the administration of 100 mg/kg STZ 
i.p. Animals were sacrificed at the indicated times. The 
O hr time point refers to 3 and 2 hr following BG and STZ 
treatment, respectively. MGMT activity was expressed as 
a percentage of activity measured in untreated 
xenografts. Measurements of STZ alone at 0, 24, and 48 
hr, BG and BG+STZ at the 0 and 6 hr time points represent 
the mean MGMT activity of two animals. The remaining 
data points represent the mean and SD of three animals. 
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combination of both agents at one hour intervals and were 
sacrificed at times illustrated in Figure 5.3. Figure 
5.3 illustrates the effectiveness of the combination of 
BG and STZ on the inactivation and recovery of MGMT 
activity in SF767 xenografts. As a single agent, STZ 
(100 mg/kg) did not appreciably affect MGMT activity in 
the xenografts whereas, complete inhibition of MGMT 
activity for 12 hr wasobserved following BG (80 mg/kg) 
administration. Thereafter, MGMT recovered to 
approximately 40% of control levels by 24 hr. Sequenced 
administration of BG (80 mg/kg) and STZ (100 mg/kg) 
produced a slower recovery rate of MGMT activity than BG 
alone. The combination produced near complete inhibition 
of MGMT activity for 24 hr. Thereafter, the tumors 
recovered control levels of MGMT activity by 48 hr. 
These data were consistent with the in vitro observations 
in that the combination of BG+STZ produced extended 
depletion of MGMT for nearly 24 hr. These data further 
suggest that the sequential administration of BG and STZ 
probably allows a greater number of STZ induced 0 6 -
methylguanine lesions in DNA to persist and deplete MGMT 
for 24 hr in the xenografts. Nude mice bearing SF767 
xenografts were sequentially administered the maximally 
tolerated doses of BG, STZ, and BCNU to test whether this 
three-drug combination would provide greater anti-tumor 
activity than BG+BCNU. Figure 5.4 illustrates the anti-
Figure 5.4: 
Tumor growth inhibition assay utilizing subcutaneously implanted SF767 xenografts. 
Nude mice carry the xenografts were injected i.p. with BG (80 mg/kg), STZ (100 
mg/kg), and/or BCNU (15 mg/kg) at one hour intervals. Each data point represents 
the mean percent change in tumor volumes of 5-9 animals. The individual tumor 
volumes throughout the study were normalized to pretreatment values for each 
individual tumor. Panel A, B, and C depict the anti-tumor activity in animals 
receiving the combination of STZ+BCNU, BG+BCNU, BG+STZ+BCNU, respectively. Within 
panel D, the tumor growth curves of untreated, BCNU, BG+BCNU, STZ+BCNU, 
BG+STZ+BCNU treated animals are reproduced for comparison. Statistical analysis, 
the data were analyzed with an multivariate ANOVA using repeated measures with a 
post-hoc test of single degree of freedom contrast. The analysis was performed 
with the SYSTAT~ statistical package. 
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tumor activity of all combinations of BG, STZ, and BCNU. 
Panels A, B, and C depict the results of tumor growth 
inhibition assays in animals receiving STZ+BCNU, BG+BCNU, 
and BG+STZ+BCNU, respectively. The combination of 
STZ+BCNU produced significantly greater inhibition of 
tumor growth on days 20 and 23 (p < 0.02) than untreated 
controls. However, BG which depleted xenograft MGMT for 
12 hours produced significant inhibition of tumor growth 
for 9-23 days relative to the untreated controls (p < 
0.02). These results are consistent with the 
observations made by Mitchell et. al (1992) in that the 
combination of BG+BCNU produced significant inhibition of 
SF767 xenograft growth for greater than 20 days. 
Similarly, the three drug combination of BG+STZ+BCNU also 
significantly inhibited tumor growth for 23 days as 
compared to the untreated controls (p < 0.01). However, 
tumor regressions, defined as reductions in tumor volume 
over two consecutive measurements, were not observed in 
any of the tumors treated with the various combinations. 
In panel D, the tumor growth rates from untreated animals 
and those treated with BCNU, STZ+BCNU, BG+BCNU and 
BG+STZ+BCNU are reproduced for comparison. The 
combination of BG+BCNU produced significantly greater 
anti-tumor activity on days 9, 12, 17, and 20 (p < 0.03) 
than STZ+BCNU. Similarly, the combination of BG+STZ+BCNU 
produced greater anti-tumor activity than STZ+BCNU on 
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Table 5.4: 
Toxicities of STZ, BCNU, or the combinations of BG+STZ, 
BG+BCNU, STZ+BCNU, BG+STZ+BCNU 
Female nude micea bearing SF767 xenograf ts were 
sequentially administered BG, STZ, and/or BCNU i.p. at 1 
hr intervals. Animal weights were measured twice weekly 
for 23 days. 
Combination 
(mg/kg) 
STZ ( 100) 
BCNU (15) 
BG ( 8 0) + STZ 
BG ( 8 0) + BCNU 
( 100) 
(15) 
STZ ( 100) + BCNU ( 15) 
BG (15) + STZ ( 100) 
+ BCNU (15) 
a NIH Swiss nude mice 
Mean maximum 
weight loss (%) 
<1 % 
<1 % 
<1 % 
4.8 % 
<1 % 
2.4 % 
b Number of animal deaths/number of animals treated 
# of animal 
deathsb 
0/7 
0/6 
0/7 
0/8 
0/7 
0/7 
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days 9 and 12 (p < 0.05). However, the three drug 
combination of BG+STZ+BCNU provided no greater anti-tumor 
activity than BG+BCNU. Additionally, the administration 
of all combinations of BG, STZ, and BCNU did not 
appreciably increase nude mouse toxicities (Table 5.4). 
These data demonstrate the feasibility using the 
combination of BG and STZ to provide extended depletion 
of MGMT for 24 hr without exacerbating BCNU toxicities. 
However, the potential therapeutic benefit offered by the 
addition of STZ to the BG+BCNU combination could not be 
demonstrated in the nude mouse subcutaneous anti-tumor 
model. The doses of STZ in this model were probably 
limited by mouse toxicities due to low levels of MGMT 
activity in host tissues. Consistent with this 
interpretation was that a single dose of 100 mg/kg STZ 
which was ineffective in depleting xenograft MGMT, 
nevertheless, produced complete ablation of renal and 
hepatic MGMT activity (Figure 5.5). These data 
demonstrate that in the nude mouse subcutaneous anti-
tumor model, BG as a single agent can produce complete 
depletion of MGMT for 12 hr, greater anti-tumor activity 
than STZ+BCNU, and anti-tumor activity equivalent to the 
three-drug combination. 
Figure 5.5: 
The effect of STZ on MGMT activity in SF767 xenografts, 
kidneys, and livers of NIH swiss nude mice. 
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Animals were injected i.p. with normal saline or STZ at 
the dose of 100 mg/kg, 200 mg/kg, and 300 mg/kg. Animals 
were sacrificed six hours following drug treatment 
animals were sacrificed. The bracketed doublet lanes 
represent MGMT activity with in a single tumor or organ 
where the 0 6 -methylguanine containing probe was incubated 
with 10 or 25 µg protein. 
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Discussion 
The primary goal of the experiments described in this 
chapter was to evaluate the effectiveness of the combined 
use of two MGMT depleting agents, BG and STZ, in 
reversing BCNU resistance in in vivo. The effects of the 
combination of BG+STZ on the repletion of MGMT and the 
enhancement of BCNU cytotoxicity was initially measured 
in cultured SF767 cells. The sequential administration 
of BG and STZ sensitized SF767 cells to BCNU cytotoxicity 
and produced a more prolonged inhibition of MGMT activity 
than either agent alone. The combined use of BG+STZ 
depleted MGMT activity for 24 hr and produced 
approximately 2 logs of synergistic BCNU cell kill. 
Consistent with these in vitro observations, the 
combination of BG+STZ also produced a more prolonged 
inhibition of MGMT activity in SF767 xenografts than 
either agent alone. The combination produced sustained 
inactivation of MGMT activity for 24 hr in the 
xenografts. Both combinations, BG+BCNU and BG+STZ+BCNU, 
produced significant inhibition of tumor growth for 9 to 
23 days after treatment and demonstrated a greater anti-
tumor activity than STZ+BCNU. 
The use of STZ as a BCNU resistance modulator in vivo 
appears to be limited. STZ at 100 mg/kg administered 
i.p. did not deplete MGMT activity in SF767 xenografts 
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but completely depleted renal and hepatic MGMT activity 
(Figure 5.5). Furthermore, a 300 mg/kg dose of STZ 
produced only a 35% reduction in xenograft MGMT (Figure 
5.5). Because this particular dose of STZ was close to 
the acute LD50 dose (360 mg/kg) (Iwasaki et al., 1976), 
the concentrations required to inhibit neoplastic MGMT 
activity would be expected to produce unacceptable host 
toxicity and thereby provide no beneficial change in the 
therapeutic index of BCNU. Similarly, Friedman et al. 
(1992) administered 300 mg/kg of STZ to BALB/c mice 
bearing medulloblastoma and glioblastoma tumors and found 
that this dose of STZ did not appreciably deplete MGMT 
activity, nor did it enhance BCNU sensitivity. Moreover, 
the DNA methylating agents temozolamide and dacarbazine 
were also ineffective in sensitizing SF767 xenografts to 
BCNU cytotoxicity (Mitchell and Dolan, 1993). These data 
suggest that methylating agents should not be used as 
single agents for CENU resistance modulation. However, 
STZ might be useful when added to the BG+BCNU regimen. 
It may be advantageous to use a MGMT depleting agent with 
intrinsic anti-tumor activity, such as STZ, in 
combination with BG. In the sequential administration of 
BG, STZ, and BCNU, BG can deplete MGMT, and thereby allow 
a greater number of STZ induced 0 6 -methylguanine lesions 
to persist and deplete MGMT for extended periods. These 
additional STZ lesions could act in concert with BCNU 
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adducts to increase the tumor cell lesion burden and 
produce a greater clinical anti-tumor activity. This 
rationale for the use of the three-drug combination was 
detailed in chapter 4. The 0 6 -methylguanine lesion has 
been considered to be more mutagenic than cytotoxic. 
However, recent observations by Kaina et al. (1991) 
demonstrated that transf ection of MGMT and ada 
complementary DNAs into MGMT deficient cells produced 
significant protection against methylating agent 
cytotoxicity, as well as mutagenesis. This cytotoxic 
potential of STZ induced 0 6 -methylguanine lesions could be 
maximized when combined with BG. 
The combination of BG+STZ+BCNU produced extended 
depletion of MGMT and greater cytotoxicity than BG+BCNU 
or STZ+BCNU in both HT-29 and SF767 cell lines. The pre-
treatment regimens which provided sustained inhibition of 
MGMT for at least 24 hr after BCNU treatment produced the 
greatest potentiation of BCNU cytotoxicity in vitro. The 
enhancement of BCNU cytotoxicity in SF767 cells was 
markedly less than in HT-29 cells. This lower 
enhancement in SF767 cell line would be expected because 
the magnitude of enhancement of CENU cytotoxicity is a 
function of cellular MGMT content (Dolan., 1991; Chen et 
al., 1993a,b), and because SF767 cells contains a 30 % 
lower MGMT activity than HT-29 cells. 
At the maximally tolerated doses, the combination of 
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BG+STZ+BCNU produced significant inhibition of tumor 
growth. However, this three-drug combination provided no 
greater anti-tumor activity than BG+BCNU. Both regimens 
produced significant inhibition of tumor growth for 9-23 
days and produced minimal host toxicity. These data 
suggest that the addition of STZ to a BG+BCNU regimen 
might not be necessary. In the mouse, ample tumor 
concentrations of BG were reached to inactivate MGMT for 
12 hr and this prolonged inhibition appeared to be 
sufficient in maximizing tumor responses in the xenograft 
model. These and other data strongly recommend the 
clinical testing of the combination of BG+BCNU (Dolan et 
al., 1990a,b; 1991; Mitchell et al., 1992; Gerson et al., 
1993; Friedman et al., 1992). However, one may not 
achieve high enough plasma concentrations of BG to 
inactivate tumors with high levels of MGMT for a 
prolonged period due to the limited solubility of the 
compound. This difficulty could be resolved by the 
repeatedly administering of BG following BCNU 
administration, or by using the combination of BG+STZ. 
Repeated administration of BG provides complete depletion 
of MGMT activity 24 hr and potentiates BCNU cytotoxicity 
in cultured cells and tumor xenografts (Gerson et al., 
1993). Alternatively, the combined use of BG and STZ 
could not only provide extended depletion of MGMT, but 
also the addition of STZ-induced DNA damage could 
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potentially contribute to clinical anti-tumor activity. 
The advantages and disadvantages of the combined use of 
BG and STZ in BCNU resistance modulation is further 
discussed below. 
CHAPTER VI 
SUMMARY 
The experiments described within this dissertation 
tested whether extended depletion of MGMT activity 
following BG, dBG, and/or STZ was required for maximal 
enhancement of BCNU cytotoxicity in CENU resistant cell 
lines. The potentiation of BCNU cytotoxicity was 
examined after complete inhibition, partial or complete 
recovery of MGMT activity 24 hr following BG, dBG, and 
STZ treatment. 
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The pretreatment regimens which provided the greatest 
potentiation of BCNU cytotoxicity were those exhibiting 
the most prolonged depletion of MGMT activity. Treatment 
of HT-29 cells with a 10 µM dose of BG resulted in 
complete inactivation of MGMT immediately after drug 
treatment, with a recovery of approximately 15% of 
control activity in 3-24 hr. This partial recovery of 
MGMT activity was completely inhibited for 24 hr by 
combining BG (10 µM) with STZ (1.0 mM), or by increasing 
the dose of BG to 100 µM. The prolonged depletion of 
MGMT activity provided by the combination of BG (10 µM) + 
STZ (1.0 mM) or BG (100 µM) was associated with a greater 
enhancement of BCNU cytotoxicity than the dose of lOµM 
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BG. Additionally, the recovery rate of MGMT activity 
following BG (100 µM) or dBG (1.0 mM) treatment was 
modulated by repeated washing of cells with complete 
medium. Subsequent to BG (100 µM) or dBG (1.0 mM) 
treatment, MGMT activity was completely inactivated for 
24 hr. Additionally, this pretreatment regimen enhanced 
BCNU cytotoxicity by 3 logs. MGMT activity recovered to 
control levels by 24 hr, and BCNU cell kill was 
coordinately reduced to less than one log when cells were 
pretreated with BG or dBG and washed four times with 
serum containing medium. When this recovery was 
completely inhibited for 24 hr by combining BG or dBG 
with a 2.5 mM dose of STZ, BCNU cytotoxicity was 
potentiated by 4 logs. These data indicate that MGMT 
should be depleted prior to, and for an extended period 
following BCNU treatment. The extended depletion of MGMT 
may allow an increased number of BCNU interstrand cross-
links resulting in greater cytotoxicity. Furthermore, the 
sequential administration of the direct MGMT depleting 
agents BG or dBG, and STZ probably results in a greater 
number of STZ-induced 0 6 -methylguanine lesions which are 
responsible for the extended depletion of MGMT. The 
consistently greater enhancement of BCNU cytotoxicity by 
the combination of BG+STZ or dBG+STZ than by BG alone 
under conditions of comparable MGMT depletion, suggests 
that the greater number of STZ lesions act in concert 
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with BCNU alkylation to produce the greater cytotoxicity 
in vitro. 
This rationale for the combined use of BG and STZ in 
BCNU resistance modulation was tested in vivo utilizing 
the SF767 subcutaneous xenograft anti-tumor model. 
Consistent with the in vitro observations, the 
combination of BG+STZ produced near complete depletion of 
MGMT for 24 hr, whereas BG alone allowed a recovery of 
40% control MGMT activity by 24 hr. The sequential 
administration of BG, STZ, and BCNU, at maximally 
tolerated doses produced no greater anti-tumor activity 
than the combination of BG+BCNU in vivo. 
Collectively, these data suggest that clinical 
chemotherapeutic regimens targeting the inactivation of 
MGMT, and the reversal of BCNU resistance, should be 
optimized such that MGMT is depleted prior to, and for an 
extended period after BCNU treatment. If extended 
depletion of MGMT cannot be achieved with BG due to 
solubility limitations in a clinical setting, then this 
difficulty may be overcome in two ways: i) repeated 
administrations of BG could provide complete depletion 
for 24 hr and potentiate BCNU cytotoxicity in vitro and 
in vivo (Gerson et al., 1993); ii) alternatively, BG 
could be combined with STZ. The latter regimen could act 
as a proverbial double-edged sword. Serial 
administration of BG and STZ could not only provide 
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extended depletion of MGMT, but also the enhanced number 
of 0 6 -methylguanine lesions could contribute to anti-tumor 
activity. 
If clinical CENU resistance modulation were to require 
multiple cycles of chemotherapy, the combined use of BG 
and STZ could also prevent the possible selection of BG 
resistant tumor cells. A single point mutation within 
MGMT has been demonstrated to impair the MGMT-mediated 
repair of BG, whereas the repair of 0 6 -methylguanine in 
DNA was unaffected (Crone and Pegg, 1993). The addition 
of STZ to a BG+BCNU regimen could provide ample levels of 
0 6 - methylguanine in DNA which could inactivate BG 
resistant MGMT, and thereby facilitate BCNU cell killing. 
A potential clinical disadvantage to the BG+STZ+BCNU 
regimen could be an increased risk of secondary 
malignancies. MGMT plays a pivotal role in the 
prevention of methylating agent induced mutagenesis and 
carcinogenesis (Kaina et al., 1991; Dumenco et al., 
1993). Presentation of methylating agent-induced pro-
carcinogenic lesions when MGMT is depleted with BG could 
conceivably increase mutation rate, and thereby increase 
the possibility of secondary neoplastic transformation. 
The combination of BG+BCNU has produced promising 
results in pre-clinical studies. The clinical testing of 
this regimen should consider the importance of extended 
depletion of MGMT in maximizing CENU cytotoxicity. With 
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the development of treatment modalities which can 
selectively deliver BG to tumor cells, an increased CENU 
therapeutic index and spectrum of clinical activity is 
anticipated. 
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APPENDIX I 
Upon review of the literature concerning the 
modulation of alkylating agent resistance, Tiecher and 
Frei (1991) concluded that neoplastic drug resistance is 
multifactorial and optimal clinical modulation of such 
resistance should target multiple resistance mechanisms 
simultaneously. Utilizing this rationale, the effect of 
combined depletion of MGMT and GSH on BCNU sensitivity in 
HT-29 cells was examined (Figure A.1). Cells were 
sequentially administered BSO, BG, and BCNU. Partial and 
complete depletion of GSH and MGMT, respectively, 
resulted in a greater enhancement of BCNU cytotoxicity 
than any two-drug regimen. BG increased BCNU (100 µM) 
cell killing by approximately 1.5 logs, and the addition 
of BSO to this regimen provided an additional 0.5 log of 
cytotoxicity. These data suggest that GSH may indeed be 
a secondary mechanism of CENU resistance in CENU 
resistant cells and further development of regimens 
targeting multiple mechanisms of resistance may be 
warranted. 
Pretreatment of brain tumor cell lines with 
diflouromethylornithine (DFMO), an inhibitor of the rate 
limiting enzyme in polyamine synthesis, decreased 
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The effects of sequential administration of BSO, BG, and 
BCNU on HT-29 cytotoxicity 
Cells were treated with BSO (25 µM) and BG (10 µM) for 24 
hr and 2 hr, respectively, prior to a 1 hr exposure to 
BCNU. BSO at a dose of 25 µM produced approximately 80% 
reduction in GSH content in HT-29 cells after 24 hr of 
exposure (Hantel et al., 1991). The 10 µM dose of BG 
utilized represents the IC100 dose for MGMT inhibition 
(Chapter 3). The combination of BSO+BG was non-cytotoxic 
(data not shown) . The tissue culture and survival assay 
protocols were described in the material and methods 
section of chapter 3. The points represent the mean +/-
SD of survival values in 3 or more replicate flasks in a 
single experiment. 
spermidine and putrescine levels, and increased BCNU 
cytotoxicity (Hunget al., 1981; Seidenfeld and Komar, 
1985). The decrease in polyamine levels appears to be 
related to an increased DNA damaging effects of BCNU. 
120 
The combined depletion of MGMT and ornithine 
decarboxylase by BG and difluromethylornithine produces 
greater cytotoxicity than BG+BCNU or DFMO+BCNU (M.E. 
Dolan, personal communication) . Furthermore, the 
topoisomerase II inhibitor novobiocin markedly increases 
the antitumor effect of BCNU (Ross, 1985; Eder et al., 
1989) . This inhibition may prevent the disaggregation of 
chromosomes in the G2 and M periods of the cell cycle and 
concurrently inhibit DNA repair. Therefore, it could be 
of therapeutic interest to simultaneously deplete MGMT, 
polyamine levels and inhibit topoisomerase II. 
Modulation of multiple mechanisms of CENU resistance 
could coordinately allow a greater DNA damage and a lower 
DNA repair proficiency. The increased DNA damage or 
impairment of DNA repair would be expected to increase 
the clinical antitumor activity of BCNU than depletion of 
MGMT alone. 
Therefore, a multimodulatory approach could also 
decrease the possibility of acquired cellular resistance 
to BG. A single point mutation within the MGMT cDNA 
markedly decreases BG sensitivity, and therefore mediate 
BG resistance (Crone and Pegg, 1993). Repeated 
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administration of BG+BCNU could result in the selection 
of a subpopulation of tumor cells expressing BG resistant 
MGMT. Concurrent targeting of multiple sites of CENU 
resistance could result in a greater cell killing and 
possibly prevent the re-establishment of tumor mass by 
BG-resistant cells. 
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Figure A.2: 
The effect of increasing amounts of MGMT containing 
extract incubated with approximately 0.2 pmoles of 0 6 -
methylguanine containing DNA on the percentage of probe 
cleaved. 
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The radiolabelled probe was incubated with 0-100 µg of 
HT-29 whole cell sonicate for 2 hr at 37°C. The protocol 
used in this experiment was described in the "Methods and 
Materials" section of chapter 3. 
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